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Abstract 
Ellis, David Harold. M.S.,Department of Pharmacology and Toxicology, Wright State 
University, 2010. 2,3,7,8-Tetrachlordibenzo-p-dioxin mediated  Immune suppression 
through interactions at the 3 Immunoglobulin Heavy Chain Regulatory Region 
Enhancers 
 
 
2,3,7,8-Tetrachlordibenzo-p-dioxin (TCDD) is a potent toxin which inhibits the antibody 
response of B cells. The 3IgHRR which is involved in transcriptional regulation of the 
heavy-chain polypeptide of antibodies is inhibited by TCDD.  The hs1,2 enhancer region, 
isolated from the 3IgHRR, is also inhibited while the isolated hs4 is activated by TCDD. 
This project sought to determine if that dichotomy in effects results from interactions at 
enhancer-specific binding sites for AhR, thought to mediate transcriptional effects of 
TCDD, and NFB, a transcription factor involved in B cell activation.  Here, I report a 
difference in the effect of TCDD on transcriptional activity of the 3IgHRR and the 
isolated hs3b/hs4 enhancer pair, in the context of chromatin. I also demonstrate reduced 
binding of proteins to the hs1,2 and hs4 enhancer sequences containing both AhR and 
NFB binding sites compared to single site sequences, suggesting that an interaction 
between the proteins alters their binding to the enhancers. 
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Introduction 
The Immune System 
The immune system defends the body from infectious organisms and protects it 
from damage by foreign molecules. It is composed of the innate and the adaptive immune 
responses. Innate immunity is the body’s immediate response to threats. It includes the 
epithelial barrier which blocks entry to the body; phagocytic cells which engulf microbes, 
foreign materials, and dead cells; natural killer cells which destroy infected or foreign 
cells; and the complement system which opsonizes or marks microbes for removal or 
kills them directly. Adaptive immunity is the body’s response to specific threats and 
includes the activity of lymphocytes and their effecter molecules: antibodies and 
cytokines. Adaptive immunity can be divided in to humoral and cell-mediated immunity. 
Humoral immunity is directed by B cells and involves production and secretion of 
antibodies, or soluble immunoglobulin molecules.  
Immunoglobulins (Ig) are polypeptides made of two heavy and two light chain 
peptides linked by disulfide bonds. They are produced by all B cells as membrane-bound, 
B Cell Receptors (BCR). When a B cell is activated by binding of its BCR by antigen and 
accessory receptor binding, B cells proliferate and produce soluble Ig which is secreted to 
extracellular spaces so it can opsonize and neutralize antigens, activate the complement 
cascade, and activate phagocytic cells. One heavy and one light chain come together to 
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form each arm of an antibody. The heavy and light chains on the Ig are each composed of 
a constant region and variable region (Ig structure and function reviewed by (Schroeder, 
et al., 2010). On each arm of the antibody, a light chain variable region (VL) and heavy 
chain variable region (VH) create an antigen binding pocket. Antigen specificity or 
idiotype is generated by a series of genetic rearrangements which occur in maturing or 
activated B cells. Germline rearrangement or somatic recombination of V and J genes in 
the VL and the V, D, and J genes of the VH is the first step in creating a diverse array of 
immunoglobulin binding pockets. That diversity is increased by “junctional diversity” 
through which the nucleotide sequence at the recombined junctions can be altered during 
somatic recombination. These events occur during B cell maturation. When a mature B 
cell is stimulated, somatic hypermutation can also change the antigen binding site 
through random point mutations during B cell proliferation. While somatic recombination 
and junctional diversity increase antigen binding diversity in the B cell repertoire, 
somatic hypermutation can increase the binding affinity of an antigen-specific antibody.  
The isotype or class of an antibody is determined by which heavy chain constant region is 
expressed. There are five main classes of antibody: IgM, IgD, IgG, IgA, and IgE encoded 
by constant regions within the heavy chain gene locus (Figure 1).  
 
Figure 1 The Ig Heavy Chain Gene Locus: VH – variable heavy chain promoter; VDJ – 
variable region defining antigen specificity; E - mu enhancer; s – switch region for class 
switch recombination; , , 3, 1, 2b, 2a, ,  – heavy chain constant region isotypes 
producing IgM, IgD, IgG3, IgG1, IgG2b, IgG2a, IgE, and IgA respectively. 
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The first gene downstream of VDJ in the germline sequence is  which produces 
the IgM isotype, a large pentameric antibody with lower specificity and limited function 
compared to other isotypes. IgD mainly exists as a membrane receptor. IgG is smaller, 
has greater antigen specificity, and is more flexible than other isotypes. IgG is the most 
common isotype and can easily move in to extracellular spaces and across the placental 
barrier. IgA is produced in the greatest abundance, mainly on mucosal surfaces where it 
controls bacterial populations. IgE is associated with allergic reactions and can produce a 
strong inflammatory response and may also be important against parasites. Each Ig class 
has different characteristics giving the antibody particular functions. The first heavy 
chain gene downstream of the rearranged VDJ region determines the class of antibody 
produced. The class of antibody produced by a B cell can change upon activation through 
class switch recombination. During recombination, regions within the heavy chain gene 
are shifted, irreversibly removing some heavy chain regions and placing a different 
region immediately downstream of the VDJ (Figure 2). Class switch recombination 
allows B cells to produce antibody with greater affinity for a specific antigen and a class 
with optimal physical characteristics for that antigen. 
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Figure 2 Class Switched Heavy Chain Gene Locus: heavy chain constant regions  
through γ1 have been cleaved from the locus and γ2b has become the first constant region 
downstream of the VDJ. The cell will now produce antibody with the same idiotype but 
of the γ2b isotype. 
B cells require two signals for activation leading to antibody secretion. Some 
antigens can provide both signals themselves by binding more than one receptor and/or 
cross linking BCRs (Vos, et al., 2000). They are called T- independent antigens. Other 
antigens must be processed and displayed on the B-cell surface through major 
histocompatibility complex (MHC) receptor so that a T cell will bind and activate the B 
cell (Bishop, et al., 2001). They are called T-dependent antigens.  When a B cell is 
activated, it produces soluble antibodies and proliferates, undergoing somatic 
hypermutation in attempt to increase binding affinity for the antigen which caused B-cell 
activation. For T-dependent antigens, the activated T cell will produce cytokines which 
stimulate the B cell to increase antibody production. The activated B cell will proliferate, 
undergo class switch recombination, and differentiate: some of the new cells will become 
short-lived plasma cells whose only function is to produce and secrete antibody while 
other daughter cells will become long-lived memory B cells, able to respond quickly with 
high affinity antibody during future encounters with the same antigen. 
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Cell-mediated immunity is directed by T cells. When activated, T cells produce 
signals which can activate phagocytic cells to kill internalized microbes, infected cells to 
undergo apoptosis, and other immune cells to migrate in to the tissue and initiate an 
immune response. T cells have membrane-bound receptors (TCR) similar to the Ig 
receptors of B cells (Rojo, et al., 2008) with antigen binding diversity generated by the 
same mechanisms (Livák, 2004). The T cell is activated when the TCR binds antigens 
displayed on MHC proteins of antigen presenting cells such as dendritic cells, 
macrophages, or B cells, and an accessory receptor is activated by its ligand on the target 
cell (Bonilla, et al., 2010). Activated T cells proliferate and produce cytokines. Daughter 
cells can become one of various forms of short-lived effector T cells, producing cytokines 
appropriate for immune response to the activating antigen, or long-lived memory T cells 
cable of quickly expanding and producing cytokines in response to future encounters with 
the same antigen. 
The immune system protects the body from foreign molecules and microbes but 
that function can be affected by xenobiotics which target immune tissues or the vital 
functions of those tissues. Since immune responses rely on a variety of processes such as 
receptor activation, signal transduction, cellular proliferation, activation of transcription, 
and protein production, it is susceptible to modulation by xenobiotics that target any one 
of those processes. Environmental contaminants such as halogenated aromatic 
hydrocarbons are known to alter immune function. 
2,3,7,8-Tetrachlorodibenzo-p-dioxin 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a halogenated aromatic 
hydrocarbon of natural and synthetic origin with potent toxic effects.  It is best known as 
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a manufacturing by-product in the pesticide, herbicide, and paper industries, but it can be 
produced anytime an organic substance is burned in the presence of chlorine 
(Altarawneh, et al., 2009; Dyke, et al., 1997; Huang, et al., 1995). Chlorine is ubiquitous, 
so TCDD can be produced during most combustion processes including the burning of 
petroleum based fuels, waste incineration, forest fires, or smoking tobacco. There is a 
great potential, therefore, for repeated TCDD exposure in the natural environment. 
TCDD is persistent in the body (Geusau, et al., 2002). Its elimination half-life in humans 
can range from 1 to 10 years, increasing with age and body fat content but inverse to 
concentration in the body (Kerger, et al., 2006; Pirkle, et al., 1989; van der Molen, et al., 
1998). Due to its long half-life and lipid partitioning, TCDD can bioaccumulate, 
increasing total body burden with each subsequent exposure (Körner, et al., 2002), which 
introduces another route of human exposure: from food animals which have accumulated 
TCDD in their tissues.  Many, if not all of TCDD’s effects are mediated by the Aryl 
Hydrocarbon Receptor (AhR) (Okey, et al., 1994; Fernandez-Salguero, et al., 1996). 
Since it is the most potent AhR ligand known, TCDD is used as a prototype to study AhR 
ligands in general.  Other ligands include pollutants such as other halogenated and 
polycyclic aromatic hydrocarbons (HAH and PAH), polychlorinated dibenofurans 
(PCDF) and polychlorinated biphenyls (PCB); and natural compounds such as the 
flavenoids (found in fruits, vegetables, green tea, and wine), tetrapyrroles (e.g. bilirubin), 
and indoles (from cruciferous vegetables) (Denison, et al., 2003; Phelan, et al., 1998; 
Fukuda, et al., 2007; Medjakovic, et al., 2008; Sinal, et al., 1997). The AhR-mediated 
effects of TCDD might also be associated with these other ligands.  It is, therefore, 
important that we understand those effects and the mechanism by which they are 
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accomplished so we can better predict the risks associated with exposure to TCDD and 
other AhR ligands. 
In animals or in animal cell models, TCDD causes a host of adverse effects 
ranging from chloracne or chloaracne-like lesions to mortality (Poland, et al., 1982; 
Pohjanvirta, et al., 1994). Immunological effects were recognized as early as 1972 when 
Buu-Hoï et. al. (Buu-Hoï, et al., 1972) reported hematological changes and thymic 
atrophy in rats associated with a single dose of TCDD. The thymus is the principal organ 
for production and maturation of T cells which, as discussed above, have roles in both 
cell-mediated and humoral immunity. Gupta et. al. (Gupta, et al., 1973) and Harris et. al. 
(Harris, et al., 1973) identified thymic atrophy as the most sensitive indicator of TCDD 
exposure in guinea pigs and mice and rats.  Small spleen size and loss of lymphoid cells 
from the spleen and lymph nodes also resulted from TCDD exposure. The spleen filters 
antigens and spent red blood cells from the blood while lymph nodes trap antigens in the 
lymphatic system; both facilitate an immune response by fostering the interaction of 
antigens, B cells, and T cells.  
TCDD was shown in those early studies to effect two lymphoid tissues important 
for immune response and alter the number of immune cells present in the blood and 
lymphatic system.  In addition, Vos et. al. (Vos, et al., 1973) connected those changes in 
immune tissues to functional deficits by reporting that TCDD can suppress both cell-
mediated and humoral function in guinea pigs and cell-mediated immunity in mice. In the 
guinea pig, there was clearly a dose dependent decrease in tetanus toxoid secondary 
response antibody levels (humoral) and in the tuberculin toxin delayed skin 
hypersensitivity test (cell-mediated) during the course of 8 weekly doses of TCDD. In 
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mice, the cell-mediated response of splenocytes from a TCDD-treated donor to an 
untreated, hybrid host’s lymph node (graft versus host assay - GVH) was inhibited in a 
dose dependent manner, suggesting a decrease in cell-mediated immunity. Further studies 
by Thigpen et. al. (Thigpen, et al., 1975) demonstrated that TCDD increased 
susceptibility of mice to Salmonella bern. As little as 1 µg of TCDD per Kg body weight 
per week (µg/Kg/wk) caused an increase in mortality yet the typical TCDD-related 
lesions of the liver and thymus did not occur at doses below 10 µg/Kg/wk. The ability of 
mice to fight S. bern infection was inhibited, therefore, at doses which did not produce 
lesions typical of TCDD toxicity. S. bern is an intracellular pathogen which normally can 
only be cleared by a cell-mediated immune response, suggesting that cell-mediated 
immunity was affected; however, there was no change in susceptibility to Herpesvirus 
suis, a viral pathogen susceptible to both cell-mediated and humoral immune response. In 
addition, the bacterial or viral load in that infection model was artificially inflated to 
lethal levels. It is not clear whether humoral or cell-mediated immunity is more dominant 
in response to such a challenge. Finally, Vos et. al. (Vos, et al., 1978) demonstrated that 
increased susceptibility to endotoxin-producing pathogens (S. Bern) may be caused by a 
decrease in detoxification of endotoxin, not by inability to clear the infection. It is not 
clear, therefore, if the humoral or cell-mediated systems, or both were affected. Nor is the 
mechanism of effect clear since it could be caused by either a loss of immune cells (T-
cell, B-cell, phagocytic cells) or cell function; however, Vos et. al. (Vos, et al., 1974) 
studied the change in blood cell counts in mice and found that while 4 weekly doses of 25 
µg/Kg caused an increase in neutrophil counts, thymic lesions, and reduced thymic 
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weight, there was no change in lymphocyte or monocyte blood counts, suggesting that 
immune suppression is more likely caused by loss of function than loss of immune cells. 
Vecchi et. al. (Vecchi, et al., 1980) demonstrated in mice that antibody production 
is inhibited by TCDD but they did not find an effect on cellular proliferation or cell-
mediated immunity. Primary antibody production in response to both a T-cell-dependent 
antigen (sheep red blood cells – SRBC) and a T-cell-independent antigen (Type II 
pneumococcal polysaccharide) was suppressed by TCDD treatment. Since T cells are 
only involved in T-cell-dependent humoral response, this suggests that TCDD targeted B 
cells. Contradiction in results of the GVH assay to test cell-mediated immunity with those 
of Vos et. al. (Vos, et al., 1973) can be explained by their difference in controls: Vecchi 
injected inactivated cells for the control while Vos injected vehicle alone, thus the effect 
measured by Vos was probably inflated due to inadequate control of background host 
response.  In a second study, Vecchi et. al. (Vecchi, et al., 1983) confirmed that TCDD 
suppressed humoral but not cell-mediated immunity. 
Further evidence that TCDD targets B cells comes from a series of experiments 
by Dooley and Holsapple. First, they confirmed that immune suppression occurs at lower 
concentrations than other typical lesions (Holsapple, et al., 1986) and that antibody 
production is suppressed without affecting cell proliferation (Hosapple, et al., 1986). 
Similer to Vecchi’s results, TCDD inhibited antibody production in response to both T-
cell-dependent (SRBC) and T-cell-independent (LPS and DNP-Ficoll) antigens. B cells 
are necessary for both reactions but T cells are only necessary for reaction to the SRBC. 
If antibody inhibition was due to an effect on T cells, only the SRBC reaction would be 
affected. Since both reactions were affected, this suggested that B cells were the principal 
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target for inhibiting humoral immunity. To test this, they treated mice with TCDD or 
vehicle and isolated splenic B cells, T cells, and macrophages (Dooley, et al., 1988).  By 
recombining the untreated cell types with TCDD-treated cell types and stimulating the 
various cell combinations with DNP-Ficol or SRBC, they determined that antibody 
secretion was only suppressed when the B cells in the recombined population had been 
exposed to TCDD.  IgM secretion was not affected in the recombined population of T 
cells treated with TCDD and untreated B cells.  While those results convincingly 
identified B cells as the target of TCDD-mediated immune suppression, a follow-up 
study (Dooley, et al., 1990) found that antigen-specific activation of T cells was inhibited 
by TCDD. This suggests that T cells are still affected even if B cells are the principle 
target of TCDD-mediated immune suppression. 
Warren et. al. (Warren, et al., 2000) demonstrated in mice that a single dose of 
TCDD one day prior to sublethal pulmonary infection by influenza A virus caused class-
specific differences in Ig expression and greater lethality. They also reported tissue 
specific changes in T cell differentiation and cytokine production, but T cells from treated 
animals were still able to stimulate lysis of infected macrophages equivalent to those 
from control animals. The changes noted in T cell function, therefore, may be less 
important than the changes in antibody isotype switching for clearance of the virus.  In a 
follow up study, Vordestrasse et. al. (Vorderstrasse, et al., 2003) reported a similar 
conclusion: suppression of T cell function did not fully explain increased susceptibility to 
sublethal viral infection, and  impaired antibody class switching may have an impact.   
Based on this and other studies (Kerkvliet, 2009), TCDD can clearly inhibit the function 
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of T cells; however, TCDD clearly affects B cells directly and that direct effect appears 
have a greater impact on host susceptibility to immune challenges. 
Aryl Hydrocarbon Receptor 
  The Aryl Hydrocarbon Receptor (AhR), as already explained, likely mediates 
the effects of TCDD. The hallmark effect by which AhR signal transduction has been 
determined is the induction of P450 metabolizing enzyme, Aryl Hydrocarbon 
Hydroxylase (AHH) or CYP1A1. AhR is a ligand-activated, DNA-binding protein, and a 
member of the basic helix-loop-helix transcription factor family (Lees, et al., 1999).  In 
the cytoplasm, AhR is bound by a chaperone complex consisting of two heat shock 90 
proteins (hsp90)(Perdew, 1988; Wihelmsson, et al., 1990; Pongratz, et al., 1992), which 
stabilize AhR in a highly sensitive ligand-binding conformation; the X associated protein 
2 (XAP2) (also known as ARA9 or AIP)(Kazlauskas, et al., 1999; Kazlauskas, et al., 
2000; Lees, et al., 2003), which inhibits nuclear translocation and ubiquitination of AhR 
and stabilizes the chaperone complex; and p23 (Kazlauskas, et al., 1999; Kazlauskas, et 
al., 2000), which stabilizes the hsp90/AhR complex and promotes nuclear translocation 
(Figure 3).  When AhR is bound by a ligand, XAP2 disassociates and the remaining 
complex translocates to the nucleus.  In the nucleus, p23 and the hsp90 proteins are 
displaced by the Aryl-Hydrocarbon Nuclear Translocator (ARNT) protein (Wihelmsson, 
et al., 1990; McGuire, et al., 1994).  The AhR/ARNT heterodimer binds DNA at a Dioxin 
Responsive Element (DRE) and alters transcription of genes in which the DRE resides 
(Jones, et al., 1986; Jones, et al., 1986; Durrin, et al., 1987).  
12 
 
 
Figure 3 The Aryl Hydrocarbon Receptor (AhR) Signaling Pathway: Cytosolic AhR is bound 
to p23, XAP2, and two hsp90 proteins. AhR ligand (TCDD) displaces XAP2 allowing nuclear 
translocation of the remaining complex. In the nucleus, ARNT displaces p23 and the hsp90 
proteins and the AhR/ARNT complex binds to Dioxin Response Elements (DRE) and affects 
transcription of genes. 
If the effects of TCDD are mediated by the AhR and TCDD affects B-cells 
function, so one would expect to find AhR expressed in B cells and activated after TCDD 
exposure. Williams et. al. (Williams, et al., 1996) found that AhR and ARNT proteins are 
both constitutively expressed in mouse splenocytes. Using the Electrophoretic Mobility 
Shift Assay (EMSA) with a DRE probe, they showed that TCDD induced two DNA 
binding complexes (representative of the two known alleles of AhR), suggesting that 
ligand activated AhR is functional in mouse splenocytes. Interestingly, a third, 
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constitutive binding complex was also present suggesting the presence of an unreported, 
third AhR allele or an alternative binding multi-mere. Marcus et. al. (Marcus, et al., 
1998) demonstrated that LPS (T-independent) activation of mouse splenocytes also 
induced AhR, ARNT, and  CYP1A1 expression, indicating that AhR can be activated in 
B cells without an exogenous ligand present. Moreover, Crawford et. al. (Crawford, et 
al., 1997) demonstrated by inducing greater binding to a DRE- containing probe, that 
activated B cells with increased levels of AhR and ARNT may be even more sensitive to 
TCDD than resting B cells. Functional AhR is also induced in CD40L-activated human B 
cells (Allan, et al., 2005) without an exogenous ligand.  
While these studies demonstrate that AhR and ARNT can be expressed in 
splenocytes, and many effects of TCDD are mediated by the AhR, these studies do not 
prove a link between TCDD-mediated suppression of antibodies and the AhR. Sulentic 
et. al. (Sulentic, et al., 1998) demonstrated that link using two B cell lines which differ in 
susceptibility to TCDD toxicity: CH12.LX cells expressed constitutive and inducible 
AhR and ARNT, while BCL-1 cells expressed ARNT but not AhR. As expected, TCDD 
induced CYP1A1 expression and inhibited LPS-induced IgM secretion in CH12.LX but 
not in the AhR deficient BCL-1 cells. Subsequently, Sulentic et. al. (Sulentic, et al., 
2000) demonstrated that in the CH12.LX cell line, four different AhR ligands induce 
CYP1A1 and inhibit LPS-induced IgM secretion in correlation with their affinity for 
AhR. The transcriptional effects of AhR are likely transduced through binding of a 
recognition sequence in DNA, so there is likely a DRE binding site within one of the Ig 
regulatory regions. One potentially affected regulatory region is the 3 Immunoglobulin 
Heavy-Chain Regulatory Region. 
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3Immunoglobulin Heavy-Chain Regulatory Region 
The 3 Immunoglobulin Heavy-chain Regulatory Region (3IgHRR) is a group of 
enhancers located 3-prime of the heavy-chain constant regions (Figure 4). 
 
Figure 4 The Ig Heavy Chain Gene Locus with 3-Prime Enhancer Region: “hs” numbers 
refer to regions of DNA that are hypersensitive to DNase I cleavage.  
The 3IgHRR was discovered in the rat B cell (Pettersson, et al., 1990) and 
thereafter identified in mouse (Dariavach, et al., 1991; Lieberson, et al., 1991) and human 
B cells (Mills, et al., 1997). The 3IgHRR was found to have DNase I hypersensitivity 
sites which are uniquely active in B cells, being highly methylated in immature B cells 
but demethylated at different stages of B cell maturity, and hypomethylated in 
disregulated (myeloma) cells (Giannini, et al., 1993). 
Madisen and Groudine (Madisen, et al., 1994) identified the 3IgHRR as a locus 
control region able to enhance expression of a human growth hormone reporter construct. 
Arulampalam et. al. (Arulampalam, et al., 1994) demonstrated that when mature B cells 
are activated by LPS or 12-O-tetradecanylphorbol 13-acetate (TPA) the 3IgHRR 
enhanced transcription of a transgenic human -globin reporter gene. The enhancer 
activity of the 3IgHRR was shown to be restricted to B cells by lack of activity after 
transient transfection of reporter constructs into T cells (Michaelson, et al., 1995). 
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Lieberson et. al. (Lieberson, et al., 1995) demonstrated that IgG2a production is 
dependent on the 3IgHRR. Their results were confounded by use of a replacement 
fragment containing the neomycin resistance gene which was later found to affect 
transcription (Seidl, et al., 1999), by fragments of the replacement vector being found in 
non-target locations, by multiple (inactive) copies of the 3IgHRR being found on 
different chromosomes, and their deletion segment including only two of the enhancer 
regions (hs1,2 and part of hs3a). Nevertheless, they demonstrated a connection between 
the 3IgHRR and Ig gene expression. Arulampalam et. al. (Arulampalam, et al., 1996) 
confirmed those results by producing mice with rearranged IgH transgenes with and 
without the enhancer region. Mice with the 3IgHRR produced 5 to 7 fold more Ig than 
those without the enhancer region. Ong et. al. (Ong, et al., 1998) studied the relative 
contribution of enhancers to Ig gene transcription in cell lines representing different 
developmental stages of B cells. Using transient reporter constructs, they reported a shift 
in the relative contribution of the 3IgHRR and its individual enhancer regions as B cells 
differentiate, but that the full 3IgHRR was more active than cut constructs at every 
developmental stage. Furthermore, while the full 3IgHRR and pairs of enhancers 
(hs1,2/hs3a or hs4/hs3b) markedly enhanced transcription, the enhancers had little or no 
effect individually. Chauveau et. al. (Chauveau, et al., 1998) confirmed the relative 
contributions of the enhancers, demonstrating greatest activity with the full 3IgHRR in 
its natural orientation. Shi and Eckhardt (Shi, et al., 2001) further studied enhancer 
activity at different stages of B cell development through stable transfection of reporter 
constructs. Their constructs had CRE-recombinase recognition sites that allowed post-
transfection deletion of either the hs1,2 and hs3a enhancer pair or the hs4 and hs3b 
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enhancer pair. They discovered that the hs4/hs3b pair was active at both stages of 
development while the hs1,2/hs3a pair was active only in the later Ig-secreting stage. 
Manis et. al. (Manis, et al., 1998) showed that the 3IgHRR is also important for 
class switch recombination. Their results were confounded by replacement of enhancer 
segments with a neomycin resistance gene cassette known to affect transcription (Seidl, 
et al., 1999), but the importance of an uncut 3IgHRR for class switch recombination was 
sufficiently demonstrated. This was confirmed by Pinaud et. al. (Pinaud, et al., 2001) 
who deleted enhancer elements without using a replacement sequence and isotype 
switching was also inhibited in their study. TCDD was shown to inhibit IgH class 
switching in the studies by Warren et. al. (Warren, et al., 2000) and Vordestrasse et. al. 
(Vorderstrasse, et al., 2003) discussed earlier, strengthening the argument that TCDD 
may target the 3IgHRR. 
TCDD inhibits IgH gene transcription and isotype switching and the 3IgHRR is 
important in both those function, so it is not surprising that Sulentic et. al. (Sulentic, et 
al., 2000) reported finding DRE-like sites in the 3IgHRR. Using EMSA/Western, they 
demonstrated that AhR and ARNT from the nucleus of TCDD-treated B cells bound 
those DRE-like sites within the hs1,2 and hs4 enhancers. Binding of AhR to the promoter 
regions of genes, however, might induce or inhibit transcription, but there is no evidence 
for transcription of the 3IgHRR, so how could binding of the AhR/ARNT complex to the 
3IgHRR interfere with its enhancer activity? While the mechanism by which the 
3IgHRR is involved in Ig heavy-chain gene expression and rearrangement is not well 
understood, there is evidence of physical interaction between the heavy-chain gene locus 
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and the 3IgHRR (Ju, et al., 2007). Binding of the enhancer could interfere with that 
interaction. Alternatively, if that interaction is mediated by certain transcription factors, 
then perhaps AhR-mediated inhibition involves interference with the binding of other 
transcription factors. Several transcription factors bind the 3IgHRR and affect IgH 
transcription. Michaelson, et. al. (Michaelson, et al., 1996), showed that B cell Specific 
Activator Protein (BSAP), Octamer, and Nuclear Factor kappa B, Rel proteins 
(NFB/Rel) bind the hs1,2 and hs4 enhancer regions. Furthermore, they demonstrated 
using B-cell lymphoma cell lines at different stages of development that NFB appears to 
inhibit hs1,2 enhancer activity in mature B cells but activates it in plasma cells, while the 
hs4 enhancer was activated by NFB at all stages of B cell development. The binding of 
NFB/Rel proteins to the 3IgHRR, therefore, is likely important for B cell function. 
The NFB family consists of 5 protein subunits: RelA or p65, RelB, c-Rel, p50 or 
NF-B1, and p52 or NF-B2. The subunits, or NFB/Rel proteins, form homo- or 
heterodimers and bind B sites within regulated genes to affect transcription of that gene. 
They are important in immune function, having roles in B cell differentiation (Feng, et 
al., 2004; Liou, et al., 1994), B cell survival and proliferation (Tumang, et al., 1998; 
Grumont, et al., 1998), and B cell activation and Ig class switch recombination 
(Bhattacharya, et al., 2002; Gerondakis, et al., 1998; Gugasyan, et al., 2000; Lin, et al., 
1998).  
Not only do NFB/Rel proteins bind sites on the 3IgHRR, but their binding 
changes after TCDD exposure. Puga et. al. (Puga, et al., 2000) demonstrated using 
EMSA that in mouse Hepa1 cells, TCDD induces DNA binding of NFB/Rel proteins. In 
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addition, EMSA/Western showed that the binding complex consisted mainly of p50 
homodimers; however, only p65 and p50 were probed in the Western analysis. 
Baglole et. al. (Baglole, et al., 2008) demonstrated a similar effect in mouse 
primary lung fibroblast cells. The cells were transfected with a NFB-luciferase-reporter 
plasmid and activated with TPA after AhR induction using cigarette smoke extract. The 
NFB-regulated reporter plasmid was inhibited when AhR was induced in competent 
mouse cells, but not in AhR-null cells, suggesting that AhR suppresses NFB-regulated 
transcription. Moreover, they showed that when AhR was induced, RelB expression and 
nuclear localization decreased, but again, only two of the NFB/Rel proteins were probed 
(RelA and RelB).  
AhR appears to also interact directly with NFB/Rel proteins. Vogel et. al. 
(Vogel, et al., 2007) found using the EMSA supershift assay, that AhR and RelB 
mutually bind a site they termed the “RelBAhRE” site in the IL-8 promoter. They did not 
find ARNT or RelA in the binding complex. Further study with co-immunoprecipitation 
revealed that AhR and RelB physically associate, and ChIP analysis confirmed that the 
AhR/RelB complex was bound to the RelBAhRE site in the IL-8 promoter. In that study, 
TCDD and forskalin (an adenylate cyclase activator) induced binding of the AhR/RelB 
complex to the IL-8 promoter, but LPS did not;  however, LPS did induce binding to a 
mutant probe that more closely resembled a consensus B site but the proteins in that 
binding complex were not identified. 
Tian et. al.(Tian, et al., 1999) indentified physical interaction between AhR and 
RelA in reciprocal co-immunoprecipitation experiments. When they activated NFB by 
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TNF treatment or over expressed RelA, an AhR-regulated reporter plasmid was 
inhibited, indicating that the RelA/AhR interaction may inhibit AhR-mediated 
transcription. Likewise, activation of AhR by β-naphthoflavone or TCDD inhibited 
activation of a NFB-regulated reporter plasmid, indicating that AhR and RelA-mediated 
transcription are mutually inhibited by the AhR/RelA interaction. Perhaps RelA has a 
greater affinity than ARNT for AhR, sequestering AhR from its transcription partner. 
They used whole cell lysates, which brings to question the difference between AhR and 
RelA in the cytoplasm versus the nucleus, but Kim et. al. (Kim, et al., 2000) compared 
cytoplasmic and nuclear extracts and found that a greater amount of AhR co-precipitated 
with RelA in cytoplasmic protein extracts than in nuclear protein extracts. This suggests 
that RelA is displaced by ARNT in the nucleaus, so it may not have greater affinity for 
AhR than ARNT. Using EMSA supershift, three B binding complexes were identified: 
p50 homodimer, p65/p50 heterodimer, and AhR/p65 heterodimer, suggesting that either 
the AhR/p65 complex is inhibitory, or that sequestering of p65 in complex with AhR 
allows a greater amount of p50 homodimer binding, which is generally an inhibitory 
complex. 
It is clear from these studies that AhR and the NFB/Rel proteins can associate 
with each other and affect their respective transcriptional activities, and in B cells, 
Sulentic et. al. (Sulentic, et al., 2004) demonstrated using the EMSA/Western assay, a 
TCDD-induced increase in binding of AhR and p65, and possibly RelB and cRel to the 
hs4 enhancer region. The assay was conducted with nuclear proteins from resting (not 
activated by antigen) cells, suggesting that both the AhR and NFB/Rel proteins were 
activated by TCDD exposure and translocated to the nucleus. The DRE and B sites in 
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the hs4 enhancer region overlap, but those sites in the hs1,2 enhancer are separated. 
Knowing now, that the AhR and NFB/Rel proteins can interact and alter each other’s 
transcriptional regulation, it would be interesting to compare how binding changes after 
TCDD exposure and after activation by antigen between the distant sites in the hs1,2 and 
overlapping sites in the hs4 enhancers. In fact, Sulentic et. al. (Sulentic, et al., 2004) 
found that TCDD exposure had a different effect on the hs1,2 and hs4 regions of the 
3IgHRR when isolated from each other. They used luciferase reporter plasmids regulated 
by either the 3IgHRR or the hs1,2 enhancer or the hs4 enhancer. TCDD inhibited 
3IgHRR-regulated and hs1,2-regulated transcription, but synergistically activated hs4-
regulated transcription. Mutating the hs4 DRE or B site reduced LPS activation with 
and without TCDD. In a follow up study, Sulentic et. al. (Sulentic, et al., 2004) made 
new reporter plasmids with the hs4 enhancer region reduced to the 42 base pairs 
surrounding the overlapping DRE and B sites in order to eliminate the effect of other 
transcriptional elements that bind the enhancer. In this study, TCDD alone induced 
transcriptional activity, which was greatly increased by LPS treatment; activity was again 
eliminated by mutation of the DRE or B site. I propose, therefore, that the dichotomy in 
the effects of TCDD on the hs1,2 and hs4 enhancers of the 3IgHRR is mediated by an 
AhR-mediated alteration in NFB/Rel proteins binding within the enhancers. 
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Hypothesis and Strategic Aims 
My hypothesis is that the dichotomy in the effects of TCDD on the hs1,2 and hs4 
enhancers of the 3IgHRR is mediated by an AhR-mediated alteration in NFB/Rel 
proteins binding within the enhancers. I used two specific aims to test this hypothesis. 
First, the dichotomy in effect was discovered in transient expression experiments, so I 
sought to demonstrate that the TCDD-induced dichotomy in hs4 and hs1,2 activity seen 
in a transient expression model is reflective of 3IgHRR transcriptional regulation in the 
context of chromatin. I made clones of CH12.LX cells that stably expressed a 2b mini-
locus consisting of variable heavy chain coding sequences and γ2b constant region 
sequences regulated by the variable heavy chain promoter and four of the 3 enhancers. 
LoxP sites were located 5-prime of the hs3a and 3-prime of the hs1,2 enhancers. Cre-
recombinase cut the transgene at each LoxP site and recombined the DNA, excising the 
targeted sequence to form the 2bhs3a1,2 transgene. I tested those recombined clones 
for the effect of TCDD on the transgene which, after cre-recombination, was regulated by 
the hs3b and hs4 enhancers only. 
The second aim was to demonstrate that TCDD causes a qualitative shift in the 
NFB/Rel proteins that bind B sites within the hs1,2 and hs4 enhancers using the 
Electrophoretic Mobility Shift Assay with Western Blot analysis (EMSA/Western). The 
EMSA makes it possible to predict the binding of nuclear proteins to specific DNA 
sequences and the Western allows the identification of specific proteins bound to the 
DNA. 
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Materials and Methods  
Materials 
RPMI 1640, nonessential amino acids, sodium pyruvate, 2-mercaptoethanol, 
penicillin, and HBSS were from Mediatech, INC. (Manassas, VA). HEPES, DMSO, 
ethidium bromide, and G418 disulfate were from Sigma (St Lewis, MO). Hyclone bovine 
calf serum (BCS) was from ThermoScientific (Rockford, IL).  EcoR1 and Not 1 
restriction digest enzymes and React buffers were from Invitrogen (Carlsbad, CA).  
HindIII restriction digest enzyme was from BioRad (Hercules, CA). Pvu1 and Xho1 
enzymes for linearizing plasmids were from Promega (Madison, WI). IGEPAL CA630 
was from MP Biomedicals (Aurora, OH). Complete-Mini Protease Inhibitor Cocktail, 
Poly[d(I-C)], and ABTS were from Roche (Indianapolis, IN). Bovine Serum Albumin 
(BSA) was from Calbiochem (La Jola, CA). TCDD was from AccuStandard (New 
Haven, CT). GAM (goat anti-mouse) capture antibody and GAM-HRP conjugate used in 
the ELISA were from Southern Biotech (Birmingham, AL). Purified moust IgG2b, and 
GAM-HRP conjugate used in the Western was from Bethyl Laboratories (Montgomery, 
TX). Anti-AhR antibodies were from Abcam (Cambridge, UK). Anti-Rel antibodies were 
from Santa Cruze Biotechnology (Santa Cruze, CA). HotMaster Taq DNA polymerase 
and buffers were from 5 Prime (Gaithersburg, MD). sNTP solutions were from Applied 
Biosystems (Foster City, CA).  Easytides Adenosine 5’-triphosphate [ -32P]  was from 
Perkin Elmer (Boston, MA). Select-D G25 STE spin columns were from IBI Scientific 
(Peosta, IA).  pEGFP-CRE plasmid, γ2b-LoxPhs3a1,2 plasmid, and NEO plasmid were 
all kind gifts from Dr. Laural Eckhardt, City University of New York (New York, NY). 
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CH12.LX cells were a generous gift from Dr. Geoffrey Haughton (University of North 
Carolina, Chapel Hill, NC) via Dr. Norbert Kaminski (Michigan State University, East 
Lansing, MI). 
Cell Model, Culture Conditions, Viability, and Transfection 
CH12.LX cells are a B cell lymphoma line derived from an in vitro culture of 
CH12 lymphoma cells (Bishop, et al., 1986) which itself was derived by intraperitoneal 
transfer of hyperimmunized spleen cells to a thymectomized and irradiated mouse 
(Arnold, et al., 1983; Lanier, et al., 1982).  The CH12.LX cells and their derivatives were 
cultured at 37
0
C in a humidified, CO2-enriched (5%) atmosphere using RPMI 1640 
growth medium supplemented with 13.5 mM HEPES, 0.1 mM nonessential amino acids, 
1 mM Sodium Pyruvate, 50 mM 2-mercaptoethanol, 100 U/mL streptomycin, 100 U/mL 
penicillin, and 10% HyClone BCS. 
Viability and cell concentration were measure on the ViCell cell viability analyzer 
(Beckman Coulter, Fullerton, CA). Culture flasks were vigorously swirled to suspend 
cells and divide cell clumps then a 10 mL serological pipet was used to pipette the culture 
up and down to further divide cell clumps and mix the culture before transferring 1 mL of 
culture to a ViCell cuvette for automated counting. In smaller cultures or samples, cells 
were thoroughly mixed and clumps divided using a pipette and an appropriate aliquot 
was diluted to a total of 1 mL in 1x PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4 
x 7 H2O, 1.4 mM KH2PO4) in a ViCell cuvette.  
All transfections were accomplished by electroporation using an ECM 360 
Electro Cell Manipulator (BTX, Hawthorne, NY). Cells were cultured to near-confluence 
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in complete medium and viability and concentration were measure on the ViCell. An 
appropriate volume containing 1.10 x 10
7
 viable cells per transfection cuvette was 
transferred to a centrifuge tube and the cells pelleted by centrifugation at 200 to 300 x g 
for 5 minutes. The pellet was resuspended in a total of 220 μL of fresh culture medium 
per transfection cuvette with an appropriate amount of linearized or circular plasmid 
DNA. Transfection cuvettes with a 1 cm gap width received 200 μL of the cell and 
plasmid solution (1.0 x10
7
 cells). The cells were pulsed (2 cuvettes at once) with the 
ECM 360 set for 250 volts, 250 Farad, and 300 ohms resistance. The actual voltage 
delivered and pulse length was recorded. After electroporation, a 200 L aliquot of 
complete culture medium was added to the cuvette(s) and the entire solution transferred 
and pooled from each cuvette to an appropriate volume of pre-warmed, complete growth 
medium.  
Transfected cell stocks were stored in liquid nitrogen. The cells were cultured to 
approximate confluence in 10 mL of complete growth medium, pelleted by centrifugation 
(300xg, 5 min) and resuspended in 2.5 mL of BCS which was then mixed with 2.5 mL of 
complete medium containing 20% dimethylsulfoxide (DMSO). Aliquots of that cell 
solution were transfered to 1 mL cryo-vials, packed in Styrofoam and frozen overnight at 
-80 
0
C. The vials were then transferred to a liquid nitrogen storage. The cells were 
recovered from storage by transfer to a 40 
0
C water bath until almost completely thawed. 
Then the cells were transferred to a culture tube containing 0.2 mL of complete medium 
at room temperature. At 3 minute intervals, with occasional swirling to mix, increasing 
volumes (0.4, 0.8, 1.6, and 3.2 mL) of complete medium were added. After a final 3 
minute incubation at room temperature, the cells were pelleted by centrifugation (200xg, 
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5 min), resuspended in 1 mL of complete medium, and transferred to 10 mL of complete 
medium in a 75 cm
2
 culture flask and incubated at 37 
0
C under 5% CO2. 
Producing the Parental Cell Line 
CH12.LX cells were co-transfected with a γ2b-LoxPhs3a1,2 and NEO plasmids. 
The γ2b-LoxPhs3a1,2 plasmid has been described previously (Shi, et al., 2001).  Briefly, 
the mini-locus consists of variable heavy chain coding sequences and γ2b constant region 
sequences regulated by the variable heavy chain promoter and four of the 3IgHRR 
enhancers. LoxP sites are located 5-prime of the hs3a and 3-prime of the hs1,2 enhancers 
so that cre-recombinase enzyme will delete the hs3a and hs1,2 enhancers (Figure 5). 
Plasmid integrity was tested by restriction digest with Hind III enzyme and with a 
combination of Eco R1 and Not1 enzymes. The circular plasmid was linearized with 
Pvu1 prior to transfection.  The NEO plasmid produces aminoglycoside 
phosphotransferase, conferring resistance to neomycin and to Geneticin (G418). It is a 
2kb-Not1 fragment with LoxP sites surrounding the NEO gene which was inserted to the 
Not1 site of a pBS-SK(Spe1/HindIII). It was linearized with Xho I prior to transfection. 
For restriction enzyme digestion and linearization, 1 μL of each enzyme, 1 μL of 
the appropriate buffer, and 1 µg plasmid DNA were mixed in a total volume (with 
deionized, filtered water) of 10 μL and incubated one hour at 37 
0
C. DNA was visualized 
on 0.7% or 1% agarose gel in 1x TBE with 0.5% Ethidium Bromide. 
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Figure 5 The 2b Transgene before and after Cre-Recombination: The 2b transgene on 
the2b-LoxPhs3a1,2 plasmid consists of  variable heavy chain coding sequences and γ2b 
constant region sequences regulated by the variable heavy chain promoter and four of the 
3 enhancers. LoxP sites are located 5-prime of the hs3a and 3-prime of the hs1,2 
enhancers. Cre-recombinase will cut the transgene at each LoxP site and recombine the 
flanking DNA, excising the targeted sequence to form the 2bhs3a1,2 transgene. FW is 
the annealing location for the forward PCR primer used to test for successful Cre-
recombination. RV1 is the reverse primer annealing location for PCR product indicating 
that the hs3a and hs1,2 enhancers were not deleted. RV2 is the reverse primer annealing 
location for PCR product indicating successful deletion of the enhancers.  
Transfection was accomplished by electroporation using 20 g of 2b-
LoxPhs3a1,2 plasmid and 5 µg of NEO plasmid per 1.0 x10
7
 cells. Four times more 
LoxPhs3a1,2 plasmid than NEO plasmid was used to ensure that cells incorporating the 
NEO plasmid would also incorporate the 2b-LoxPhs3a1,2 plasmid. After 
electroporation, transfected cells were transferred to 100 mL of complete culture medium 
and aliquoted to wells of 96-well plates at 100 μL per well. Plates were incubated at 37 
0
C in 5% CO2 for 48 hours before addition of 100 μL per well of complete culture 
medium containing 4 mg/mL G418. After 6 days in culture, 100 μL of medium was 
carefully removed from each well and replaced with 100 μL of fresh medium containing 
4 mg/mL of G418. Every 3 days thereafter, 100 μL of culture medium was similarly 
replaced. When a colony of cells became visible to the naked eye, it was transferred to a 
well of a 12 well plate, labeled to identify its plate and well of origin to prevent duplicate 
colony sampling, and cultured in 2 mL of fresh medium containing 2 mg/mL G418. 
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When the cell population in those wells became dense (about 6 days) they were 
transferred to 75 cm
2
 culture flasks with 10 mL of fresh culture medium containing 2 
mg/mL G418. When the viable cell population exceeded 3.0 x 10
5
 cell/mL, an aliquot 
containing 5 x 10
6
 cells was removed for storage in liquid nitrogen. Subsequent culture 
and testing were done in the absence of G418. Successful incorporation of the 2b-
LoxPhs3a1,2 transgene and estimation of the number of copies incorporated was 
accomplished by real-time PCR (described below). Transgene function was confirmed by 
LPS treatment and measurement of 2b by ELISA (described below). 
Real-Time PCR Testing for 2b-LoxPhs3a1,2 Incorporation 
Real-time PCR was used to estimate the number of 2b-LoxPhs3a1,2 loci 
incorporated in each parental clone. Genomic DNA was extracted from clones using 
GeneElute Mammalian Genomic DNA MiniPrep Kit (Sigma) and quantified using a 
NanoDrop ND-1000 Spectorphotometer (NanoDrop Technologies, Wilmington, DE). 
Real-time PCR was conducted using an AB 7500 Real Time PCR System (Applied 
Biosystems, Foster City, CA) with SYBR Green reporter dye (Applied Biosystems 
SYBR Green PCR Master Mix) in 96-well format. 20 ng of DNA and 10 pmol each of 
forward and reverse primers were amplified with the following thermal profile: 2 minutes 
at 50
0
C; 10 minutes at 95
0
C; 40 cycles of 15 seconds at 95
0
C then 1 minute at 60
0
C after 
which fluorescence was measured. DNA from each clone was amplified using primers 
for the γ2b or NEO or β-actin (see below). Threshold Cycle (CT), the cycle at which 
fluorescence becomes greater than a threshold value, was calculated by Sequence 
Detection Software (SDS v 1.2.3)(Applied Biosystems) relative to β-actin amplification. 
A dissociation run was conducted to disqualify wells with multiple or questionable 
28 
 
products: if a well had a lower melting temperature than like-product wells and/or more 
than one peak in the dissociation plot, it was omitted from the analysis.  Untransfected 
CH12.LX cells were used as a negative control while C3 cells (CH12.LX. γ2b-
LoxPhs3b4, stably transfected with a similar transgene but with LoxP sites surrounding 
the hs3b and hs4 enhancers) were used as positive controls. If the CT for γ2b in a parent 
was less than or equal to the CT for γ2b in CH12.LX then it was estimated to have one or 
more copies of the γ2b transgene, since CH12.LX cells have undergone class-switch to 
produce IgA and should not contain the 2b gene. If CT for β-actin in a parental was less 
than its own CT for γ2b, it was estimated to have less than two copies of the γ2b 
transgene, since each cell should have two copies of the β-actin gene. Each parental clone 
and control was tested in duplicate; outliers were determined by Sequence Detection 
Software protocol and disqualified from calculations.  
Primers were obtained from the Macromolecular Structure Facility, Michigan 
State University (East Lansing, MI). The primers for γ2b with a 229 base pair product 
were forward 5-CACCCATCGAGAGAACCATC-3 (CEWS63) and reverse 5-
CCAGGCAAGTGAGACTGACA-3 (CEWS64). The primers for NEO were forward 5-
TGAATGAACTGCAGGACGAG-3 (CEWS37) and reverse 5-
ATACTTTCTCGGCAGGAGCA-3 (CEWS38). The primers for -actin with a 122 base 
pair product were forward  5-GCTACAGCTTCACCACCACA-3 (CWS65) and reverse 
5-TCTCCAGGGAGGAAGAGGAT-3 (CEWS66). 
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Producing the Deletion Derivative Clones 
Enhancer deletion and isolation of deletion derivatives (CH12.LX.2b-hs3a1,2) 
was accomplished by transient expression of CRE-recombinase (CRE) and green 
fluorescent protein (GFP) and with fluorescence assisted cell sorting (FACS). Transient 
CRE and GFP expression was accomplished by transfection of cells with a pEGFP-CRE 
plasmid which encoded CRE and a GFP variant with brighter fluorescence and silent 
mutations for compatibility with mammalian cells (Dikici, et al., 2009). The integrity of 
the plasmid was tested by restriction digest with Hind III. The circular plasmid was 
introduced to cells by electroporation with actual voltage delivered at 236 volts for 1.3 
milliseconds. Transfected cells were transferred to 50 mL of complete medium and 
cultured overnight at 37 
0
C with 5% CO2. The cells were pelleted by centrifugation at 300 
xg for 5 minutes and resuspended in 2 mL of complete medium for cell sorting. Cells 
expressing GFP were separated by FACS from non-expressing cells by the Core Flow 
Cytometry Facility at Cincinnati Children’s Hospital (Cincinnati, OH). Cells expressing 
GFP were transported from the facility in 2 mL of complete medium. Upon return, cells 
were pelleted by centrifugation at 200 xg for 5 minutes, resuspended in 1 mL of complete 
medium and either underwent limiting dilution (diluted to 5 cells per mL in complete 
medium) such that 100 μL transferred to wells of a 96-well culture plate contained an 
estimated 0.5 cells, or were cultured in 5 ml of complete medium over night or for six 
days after which they underwent another limiting dilution to 0.5 cells per well. When a 
cell clump became visible to the naked eye, it was transferred to a well of a 6-well plate 
with 5 mL of complete medium and labeled with plate and well of origin to prevent 
duplicate sampling of a clonal isolate. When cells appeared confluent in 6-well plates, 
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they were transferred to a 75 cm
2
 culture flask with 10 mL of complete medium and 
assigned a new designation: Dx, where x is the isolate number. An aliquot of near 
confluent cells in 75 cm
2
 culture flasks was removed for storage of cells in liquid 
nitrogen while another aliquot was used to isolate DNA for confirmation of enhancer 
deletion. 
PCR for Confirmation of hs3a and hs1,2 Enhancer Deletion 
Deletion of the hs3a and hs1,2 enhancers was verified by PCR amplification of 
sequences specific for the 2b mini-locus before and after deletion. This was 
accomplished by using one forward primer which annealed upstream from the most 5-
prime LoxP site (preceding the hs3a enhancer), and one of two reverse primers (RV1 and 
RV2, Figure 5). RV1 annealed inside the targeted deletion so that only clones with an 
intact 2b mini-locus would have a PCR product (UNCUT). RV2 annealed downstream 
from the most 3-prime LoxP site (located after the hs1,2 enhancer) so that only clones 
which have the cut 2b mini-locus will have a PCR product (CUT). If the hs3a and hs1,2 
enhancers were not deleted, the sequence separating RV2 from the forward primer was 
too long (5389 base pairs) for a PCR product to form. The parental clone (pC13) served 
as a positive UNCUT control and a negative CUT control, while CH12.LX which does 
not contain the mini-locus was also used for a negative control.  
Primers were designed using Primer Blast (www.ncbi.nlm.nih.gov/tools/primer-
blast/) and made by the Macromolecular Structure Facility, Michigan State University 
(East Lansing, MI). Several primers were designed, ordered, and tested to find the proper 
specificity. The forward primer used had the sequence 5-
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GCCGCTAATTCCGATCATATT-3 (CEWS143). The UNCUT reverse primer (RV1) 
had the sequence 5-TTGGCTGGACGTAAACTCCT-3 (CEWS161). The UNCUT 
primer pair (CEWS143+161) should amplify a 100 base pair product from the mini-locus 
only if the enhancers were not deleted. The CUT reverse primer (RV2) had the sequence 
5-TTGCCCCAATATCCCTTAGAT-3 (CEWS144). The CUT primer pair 
(CEWS143+144) should amplify a 122 base pair product from the cut mini-locus with 
enhancers deleted but nothing from the uncut mini-locus. 
DNA was isolated using the GeneElute Mammalian Genomic DNA MiniPrep Kit 
(Sigma). PCR amplification was conducted in an Eppendorf Mastercycler (Eppendorf 
AG, Hamburg, Germany) thermocycler with HotMaster Taq DNA polymerase. 200 ng of 
genomic DNA was mixed with 0.2 mM dNTP mix, 0.2 mM forward primer, 0.2 mM 
reverse primer, 1.25 U of Taq, and 2.5 μL of 10x HotMaster Buffer, in a total volume 
(with deionized, filtered water) of 25 L. Where the DNA yield was low, the total 
volume was increased to 50 μL with appropriate increase in buffer and as close to 200 ng 
of DNA as possible. PCR products were visualized by electrophoresis in a 2% agarose 
gel in 1x TAE with 0.5% Ethidium Bromide, and imaged with a Foto/Eclipse (Fotodyne, 
Hartland, WI) dark box, COHU (Poway, CA) high performance CCD camera, and Scion 
Image 1.60c software (Scion, Frederick, Maryland). 
Screening for LPS-Inducible γ2b and the Effect of TCDD 
Cells were seeded to 12-well culture plates at 3.13 x10
4
 cell/mL in 2 mL of 
complete growth medium. For LPS-induced 2b expression in parental clones, 2.5 x10
5
 
cells were pelleted by centrifugation (200 xg, 5 minutes), resuspended in 8 mL of 
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complete medium, and aliquots transferred to the culture plate. One aliquot was left 
untreated while the others were treated with either 0.01 or 0.1 or 1.0 µg/mL of E. coli 
lipopolysaccharide (LPS) by addition of 2 μL of LPS at the appropriate concentration. 
For the effect of TCDD in parental clones, 1.25 x10
6
 cells were pelleted by centrifugation 
(200 xg, 5 minutes), resuspended in 40 mL of complete medium, and 10 mL aliquots 
transferred to culture tubes. One tube was left untreated (control), another was treated 
with 0.01% DMSO (Vh), another with 0.01% DMSO and 1 µg/mL LPS (LV), and the 
last tube was treated with 30 nM TCDD in DMSO (final is 0.01% DMSO) and 1 g/mL 
LPS (LT). 2 mL aliquots from each tube were then transferred to each of four wells of a 
12-well plate. For testing of deletion derivative clones, 6.5 mL aliquots at 3.13 x10
4
 
cell/mL were transferred to new tubes and treated with 1x PBS (NA) or 0.01% DMSO 
(Vh), or 0.01 nM, 0.1 nM, 1.0 nM, or 10 nM TCDD (T) in DMSO (final 0.01% DMSO) 
or 0.001 µg/mL, 0.01 µg/mL, 0.1 µg/mL, 1.0 µg/mL, or 10 µg/mL LPS (L) or an 
appropriate combination of 1x PBS, LPS, DMSO, and TCDD (LV or LT). 2 mL aliquots 
were transferred from each tube to duplicate wells of a 12-well culture plate 
Treated culture plates were incubated at 37 
0
C with 5% CO2 for 48 hours. Then 
cells were packed on the well bottoms by centrifugation at 3000 rpm (1811 xg) for 10 
minutes so that 1.5 mL of supernatant could be removed and discarded without losing 
cells. 0.5 mL of 1x PBS was added to each well and cells resuspended by pipetting. The 
entire volume was then transferred to a 1.5 mL centrifuge tube and the cells were pelleted 
by centrifugation at 2000 rpm for 5 minutes. The supernatant was discarded and then 
cells resuspended in 50 L of mild lysis buffer (150 mM NaCl, 2 mM EDTA, 10mM 
NaPO4,1% IGEPAL CA630) with Complete-Mini Protease Inhibitor Cocktail (Complete-
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Mini) by vortexing. The lysed cell solutions were stored at -80
0
C at least overnight. The 
lysate was then thawed on ice, vortexed to mix, cleared of cellular debris by 
centrifugation at 14000 rpm (20817 xg) for 10 minutes, and transferred to a new storage 
tube. Samples were then assayed for γ2b protein by Enzyme Linked Immunosorbent 
Assay (ELISA). 
Enzyme Linked Immunosorbent Assay (ELISA) for 2b 
Total protein in the samples was measured by Bio-Rad Protein assay following 
the manufacturer’s instructions, in 96-well format using a Spectramax Plus 384 plate 
reader (Molecular Devices, Sunnyvale, CA) with Softmax Pro software version 4.0. An 
aliquot of each sample was diluted to 0.01 g/L in 1 x PBS for use in the ELISA. 
ELISA was conducted in 96-well format using an ELx50 auto strip washer (Bio-Tek 
Instruments, Winooski, VT) and the Spectramax Plus 384 plate reader. The plates were 
coated with goat anti-mouse immunoglobulin capture antibody  by incubating at 4 
0
C 
overnight with 100 L of 3 g/mL antibody solution (0.1 M Carbonate-Sodium 
Bicarbonate buffer). Three wells were left empty as negative controls. The plates were 
rinsed with 1x PBS containing 0.05%TWEEN20 (PBS/TWEEN) and then with 
deionized, filtered water, then blocked for one hour with 200 L per well of 3% BSA in 
1x PBS with 0.05% TWEEN20 at room temperature. The plates were rinsed again with 
PBS/TWEEN and water, and then stored at -20 
0
C until use. Standards (prepared by serial 
dilution of purified mouse IgG2b) and diluted samples were added to coated ELISA 
plates in duplicate at 100 μL per well and incubated for 1 to 1.5 hours at 37 
0
C. Three 
wells coated with capture antibody were incubated with saline as “no protein” negative 
controls while a random protein sample was added to 3 wells lacking capture antibody for 
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“no capture” controls. After incubation, solutions were discarded and the plates rinsed 
with PBS/TWEEM and water. The detection antibody, goat anti-mouse Ig2b conjugated 
to horseradish peroxidase was diluted 1:60,000 in 3%BSA in 1x PBS containing 
0.05%TWEEN20 and then a 100 μL aliquot transferred to each well. The plate was then 
incubated another 1 to 1.5 hours at 37 
0
C and rinsed with PBS/TWEEN and water. 100 
μL of ABTS substrate pre-warmed to about room temperature, was then added to each 
well and the rate of substrate conversion at 37 
0
C was monitored for one hour using the 
Spectramax Plus 384 plate reader. 
The Electrophoretic Mobility Shift Assay (EMSA): 
Cell Treatment: 
Cells were seeded in complete growth medium and cultured to confluence. Cell 
viability and concentration were measured by ViCell, and then split to 3 culture flasks of 
120 mL each, at approximately 5.0 x10
5
 cells/mL. The flasks were either treated with 30 
nM TCDD (T) in DMSO (final DMSO concentration 0.019%), or 0.01% DMSO (Vh), or 
1 x PBS (NA). After 5 minutes, each of the flasks was swirled to mix and resuspend the 
cells, and then 60 mL was transferred to another flask and treated with 1 µg/mL LPS (L 
and LV and LT). The flasks were incubated at 37
0
C with 5% CO2 for one hour. Cultures 
were transferred to conical-bottom tubes and cells collected by centrifugation at 300 xg 
for 5 minutes. 
Nuclear Protein Isolation 
CH12.LX cell pellets collected after treatment were washed with 1x PBS and 
pelleted again by centrifugation at 200 xg for 5 minutes. For the homogenizer method, 
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cellular membranes were swelled by incubation in 10 mM HEPES (10 mM HEPES, pH 
8, 1 mM DTT, and Complete-mini) for 10 minutes on ice. When isolating proteins from 
spleenocytes, HB (10 mM HEPES, pH 8, 1.5 mM MgCl2, Complete-mini) was used to 
swell membranes instead of 10 mM HEPES and Hank’s Buffered Saline Solution 
(HBSS) was used in place of 1 x PBS. Cells were pelleted again to remove the HEPES or 
HB, resuspended in MDH (25 mM HEPES, pH 8, 3 mM MgCl2, 1 mM Dithiothreitol 
(DTT), Complete-mini), and transferred to a Dounce homogenizer (B pestle). Cellular 
membranes were lysed with 10 slow pestle strokes while the homogenizer was kept on 
ice and the lysed cells were transferred to a conical tube.  
For the non-ionic detergent method, CH12.LX cell or spelenocyte pellets 
collected after treatment were washed with HBSS and pelleted again, and then 
resuspended in HB and incubated on ice for 10 minutes to swell the cellular membranes. 
HB+IGEPAL (HB + 1.5% IGEPAL CA630) was then added to achieve a final IGEPAL 
CA630 concentration of 0.5% and samples incubated another 5 minutes on ice. 
The nuclei were collected after either method of membrane lysis by centrifugation 
at 1000 xg for 5 minutes and the cellular fraction (supernatant) discarded. The nuclear 
pellets were washed twice with MDHK (25 mM HEPES, pH 8, 3 mM MgCl2,  100 mM 
KCl, 1 mM DTT, Complete-mini), then resuspended in HEDK (25 mM HEPES, pH 8, 1 
mM EDTA, 400 mM KCl, 1 mM DTT, Complete-mini). Tubes were rocked on ice or 
rotated at 4 
0
C for 30 to 40 minutes for high-salt extraction of nuclear proteins. Nuclear 
debris was pelleted by centrifugation at 14000 xg for 15 minutes, and the supernatant 
(nuclear proteins) were transferred to new tubes. Protein concentrations were measured 
using a BCA Protein Assay Kit (Thermo Scientific Pierce) by following the 
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manufacturer’s instructions, either immediately from fresh samples or from an aliquot 
stored separate from the sample. Samples and protein aliquots were stored at -80 
0
C. 
Labeling Probes: 
Single stranded nucleic acid sequences and their anti-sense complements were 
ordered from the Macromolecular Structure Facility, Michigan State University (East 
Lansing, MI). The sequence for each of the probes used is shown in Table 1. 
Complementary oligomers were annealed by combining 1000 pmol of each and 
incubating them at 88
0
C for 5 minutes in a heat block and then removing the block from 
its heat source and allowing it to cool to room temperature slowly. Annealed oligomers 
were end-labeled with 
32
P by reaction with T4 Kinase using the Ready-to-Go T4 
Polynucleotide Kinase Kit (Amersham Biosciences, Piscataway, NJ): 10 pmol of 
annealed oligomer was incubated with T4 Kinase and 20 Ci of Easytides Adenosine 5-
triphosphate [ -
32
P] (Perkin Elmer, Boston, MA) for 30 minutes at 37 
0
C. Select-D G25 
STE spin columns were used to remove 
32
P not bound to DNA. The activity of the radio-
labeled probe was measured by liquid scintillation spectrometry using a TRI-CARB 1900 
TR Liquid Scintilation Counter (Packard Instrument Corp, Meridian, CT). 
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Table 1 EMSA Probes (top or sense strand): The oligonucleotides radio-labeled or used as 
unlabeled probes were ordered as complementary, single stranded DNA. Shown here is the 
sequence for the top or sense stand. 
EMSA: 
Short oligonucleotide probes were designed to include DRE and B binding sites 
from the hs4 and hs1,2 enhancer regions and were labeled as previously described. The 
probes sequences are shown in Table 1. Activity of the radio-label in counts per minute 
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(CPM) on the day of an EMSA experiment was determined by calculating the number of 
half-lives that past (p) since the probe was labeled and dividing the CPM at the time of 
label by 2 raised to the p power (      ). The probe was then diluted in HED (25 
mM HEPES, pH 8, 1 mM EDTA ) to 10,000 CPM/L. 
Nuclear proteins were diluted to 10 µg/30 L with HED and HEDK such that the 
final KCl concentration in the 30 μL binding reaction would be 80 mM for the hs1,2 
enhancer probes and 100 mM for the hs4 enhancer probes. The nuclear proteins were 
incubated at room temperature with 1 to 2 g of Poly[d(I-C)] in 25 mM HEPES, pH 8, 1 
mM EDTA, 1 mM DTT, and 80 or 100 mM KCl , for 15 minutes to engage non-specific 
binding prior to addition of radio-labeled probe. Note that earlier studies used 10 mM 
HEPES instead of 25 mM. In later studies the reaction buffer was brought to 10% 
glycerol by addition of HEDG where HED had been added previously. Antibodies for a 
supershift assay or unlabeled competitor probes, when used, were included in the last 5 
minutes of that incubation. 40,000 CPM of probe in 4 μL was added and the reaction 
incubated another 45 minutes to 1 hour at room temperature. The entire 30 μL reaction 
volume was then loaded to a 4%, 6%, or 8% polyacrylamide gel in 1x TAE (6.7 mM 
Tris, pH 8, 3.3 mM Sodium Acetate, 1 mM EDTA) in a Model P10DS Owl vertical gel 
apparatus (Owl Separation Systems, Portsmouth, NH). In earlier studies, prior to the 
addition of 10% glycerol to the reaction, loading dye was added to the reaction before 
transfer to the gel. 120 volts of electricity was applied for 6 to 10 hours, refreshing the 
upper reservoir of TAE about every 3 hours. The gel was then dried on 3 mm filter paper 
(Whatman) with one side covered by common plastic wrap and exposed to 
autoradiography film in an autoradiography cassette at -80 
0
C for 4 to 36 hours which 
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was then developed and scanned for digital documentation. In the earliest optimization 
experiments, the dried gel was exposed to a phosphoimaging plate (BASIIIs) overnight at 
room temperature, which was developed in a FujiFilm FLA 5100 (FujiFilm, Valhalla, 
NY) phosphoimager. During optimization of the EMSA, the concentration of KCl or 
Poly[d(I-C)] was varied along with the percent of polyacrylamide in the gel and timing of 
electrophoresis. Antibodies specific for AhR or one of the NFB/Rel subunits were used 
to try and supershift (cause a greater shift in mobility through the gel than binding of the 
protein alone) a probe and reveal which proteins were bound. Unlabeled probes (double 
stranded oligonucleotides annealed in the process of making a radio-labeled probe, but 
not added to a labeling reaction) were added to a reaction to compete with labeled probe 
such that proteins that bind sites on the unlabeled probe will no longer bind the labeled 
probe.  
EMSA/Western 
The EMSA reaction for an EMSA/Western was conducted as described above 
except that some of the samples were only incubated with un-labeled probe so that the 
portion of gel containing un-labeled probes could be separated from the rest prior to 
drying. The un-labeled portion of gel was rocked in transfer buffer (48 mM Tris, 39 mM 
Glycine, 0.4% SDS, 20% Methanol) at room temperature for 20 minutes, then transferred 
to PVDF membrane at 20 volts overnight. The membrane was then probed for AhR or 
one of the NFB/Rel subunits using specific antibodies. Anti-AhR was used at a 1:2000 
dilution. Anti-Rel specific for each NFB/Rel subunit was used at a 1:1000 dilution. The 
blocking buffer used during Western Blot analysis was 1% dry non-fat milk in TBS-T 
(2mM Tris, pH 7.6, 13.7 mM NaCl, 0.1% TWEEN20) and TBS-T was used for rinses. 
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The secondary antibody was goat anti-mouse immunoglobulin (GAM) conjugated to 
HRP at a 1:4000 dilution. SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific) was applied to the membrane which was then covered with common plastic 
wrap and exposed to autoradiography film for 5 seconds to 5 minutes. The film was 
developed and digitally documented as described earlier. During initial studies, some 
Western blots were visualized using a FujiFilm LAS 3000 Image Reader (FujiFilm). 
Statistical Comparisons: 
Statistical comparisons were made using Prism 5 for Windows (GraphPad) 
version 5.02. Significance was set at 95% confidence. Differences in variance were 
compared using 2-way analysis of variance (ANOVA) with a Bonferroni post-test to 
compare treatments. When only one clone was tested, a 1-way ANOVA and Bonferroni 
post-test were used. 
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Figure 6 Restriction Enzyme Digest of the 2b-LoxPhs3a1,2 and pEGFP-CRE Plasmids: 
The integrity of the plasmids was tested by restriction enzyme digest and agarose gel 
electrophoresis. Column labels show the restriction enzyme used and in parenthesis, the expected 
DNA fragment sizes after digestion with that enzyme. 
 
Results and Discussion 
The first specific aim asserting that a dichotomy in the effects of TCDD between 
the hs1,2 and hs4 enhancers observed in transient transfection studies (Sulentic, et al., 
2004) was also true in the context of chromatin, was tested by stable transfection of 
CH12.LX cells with a hs3b/hs4-regulated, 2b reporter construct. Previous studies 
(Fernando, unpublished) demonstrated inhibition of the hs3a/hs1,2-regulated construct 
after stable transfection, similar to the transient transfection study.  
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Prior to transfection, the plasmid underwent restriction fragment digestion to 
confirm its integrity. The expected restriction fragments were not produced when 
digesting the initial preparation of the 2b-LoxPhs3a1,2 plasmid ( Figure 6). The 
expected results were as follows: Hind III, bands expected at 1.3, 7.8, and 9.5 kb; Eco 
R1, bands expected at 2.0 and 16.5 kb; Not 1, bands expected at 5.3, 13.2 kb; Eco R1 + 
Not 1, bands expected at 0.4, 2.0, 2.9, and 13.2 kb; and Xbam 1, bands expected at 1.1, 
1.2, 1.4, 2.1, 3.2, 4.0, and 5.6 kb. A new preparation of  the plasmid was correctly 
digested and linearized prior to transfection (Fernando, personal communication). The 
NEO plasmid which was co-transfected for selection of successfully transfected cells did 
not appear linearized at the time of transfection (Fernando, personal communication) 
even though it was previously linearized by Xho 1 (Figure 7 Restriction Enzyme Digest and 
Linearization of the 2b-LoxPhs3a1,2 and NEO Plasmids: The integrity of the 2b-LoxPhs3a1,2 
plasmid was verified by restriction enzyme digest (column labels with expected fragment size in 
parenthesis) and agarose gel electrophoresis along with linearization of the 2b-LoxPhs3a1,2 
(Pvu1) and NEO (XhoI) plasmids.). Since circular DNA can also be incorporated to the 
genome and its efficiency of incorporation can be better or worse than linear DNA 
depending mainly on the cell line (Neumann, et al., 1886; Xie, et al., 1993; Xie, et al., 
1992; Kumar, et al., 1994; Liu, et al., 2008), the Xho 1 digested NEO was used regardless 
of its conformation. The reporter construct and NEO were co-transfected to cells by 
electroporation at a ratio of 2:1, to ensure that cells transfected with NEO were also likely 
to have been transfected with the reporter. After selection in G418-suplemented medium, 
19 individual cell colonies were isolated; however, some isolates (pC9, pC11, pC18, 
pC19) were lost during passage to a larger volume of medium. 
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Figure 7 Restriction Enzyme Digest and Linearization of the 2b-LoxPhs3a1,2 and NEO 
Plasmids: The integrity of the 2b-LoxPhs3a1,2 plasmid was verified by restriction enzyme 
digest (column labels with expected fragment size in parenthesis) and agarose gel electrophoresis 
along with linearization of the 2b-LoxPhs3a1,2 (Pvu1) and NEO (XhoI) plasmids. 
Real-time PCR was used to estimate the number of reporter constructs 
successfully transfected to parental clones. By selecting clones with only one copy of the 
reporter, I hoped to ensure efficient CRE-recombinase modification of the construct. The 
CT values for each of the parental clones (CH12.LX.2b-LoxPhs3a1,2 designated pCx , 
where x is the clonal isolate number), for the negative control (untransfected CH12.LX 
cells), and for the positive control (C3 cells) are shown in Table 2 with associated graphs 
in Figure 8. A CT value for 2b in the sample which was greater than that for the negative 
control but less than the CT for the -actin gene in the same sample was assumed to 
indicate incorporation of a single copy of the reporter construct.  
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Table 2 Threshold Crossing (CT) Values from Real Time PCR: Listed are the mean CT values 
for -actin, 2b, and NEO genes in 2b-LoxPhs3a1,2 parental clones, CH12.LX 2b-negative 
controls, and C3 Cell 2b-positive controls. 
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Figure 8 Real-Time PCR of DNA from CH12.LX.2b-LoxPhs3a1,2 Cells: Single-copy 
integration of the 2b mini-locus was estimated by real-time PCR using primers for 2b and -
actin. Shown here is fluorescence from the last 14 cycles of real-time PCR where C
T
 occurred for 
each clone. Copy number was estimated by comparison to a 2-copy control (-actin) and a 2b 
negative control (CH12.LX cell DNA) as well as a single-copy positive control (C3 cell DNA). 
The CT value for 2b in one parental (pC12) was greater than that for CH12.LX. 
Since the CH12.LX cell line produces IgA, it has undergone class switch recombination 
and its DNA should not contain a 2b constant region; however, IgM can be measured in 
CH12.LX cells, suggesting that some cells may not have undergone class switch 
recombination, or that only one copy of the heavy chain gene locus has been recombined, 
so that cells still retain a copy of the 2b gene. This explains why real-time PCR revealed 
a CT value (30.7) for 2b in the negative control, CH12.LX cells. In order to estimate 
single copy incorporation for the reporter plasmid, the CT for 2b in CH12.LX cells was 
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defined as one copy or less of the 2b gene. Since the pC12 clone had a greater CT value 
than CH12.LX, it was assumed to have less than one copy of the 2b transgene and was 
dropped from further characterization. Thirteen clones were estimated to have 
incorporated one copy of the 2b transgene. Three of the CT values for the NEO 
transgene (No DNA, CH12.LX cells, and pC6) were greater than the CT value for 2b in 
CH12.LX cells, suggesting less than one copy was present, which was expected in the No 
DNA and CH12.LX controls. Since G418 selective pressure was removed after initial 
characterization, pC6 was not disqualified for appearing to have less than one copy of the 
NEO transgene. No CT value for 2b was less than the CT value for -actin in the same 
cell, suggesting that none of the clones had more than two copies of the2b mini-locus in 
its genome. pC16 was not characterized further because its CT value for 2b was less than 
one cycle from its CT for -actin, suggesting that it may have incorporated 2 copies of the 
2b mini-locus. 
In summary, the transfection was successful: 1 of 15 clones tested incorporated 
the NEO plasmid but not the2b mini-locus; 1 of 15 incorporated more than one copy of 
the NEO plasmid; and 1 of the 15 tested may have incorporated more than one copy of 
the 2b mini-locus. Twelve of the 15 clones tested incorporated one NEO plasmid and 
one2b mini-locus. Although this seems like overwhelming success, transfection of 4 
fold more 2b plasmid than NEO may have increased the probability of selection for 
2b-positive clones, and using 20 µg of 2b plasmid per 1 x 10
7
 cells was apparently a 
good ratio to ensure single-copy incorporation.  
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The transgene copy number could have been determined with greater confidence 
by an alternative method, such as making a standard curve of the transgene by calculating 
its molecular weight and using an estimated molecular weight for CH12.LX genomic 
DNA to determine input concentration (Reisinger, et al., 2008). Alternatively, a method 
calculating the relative quantification of gene copy could have been employed (Cawthon, 
2002). Since I only needed to estimate that one transgene copy was present to ensure 
deletion of the hs3a and hs1,2 enhancers in every copy present, the method I employed 
was adequate.  
Clones which successfully incorporated the 2b transgene (CH12.LX.γ2b-
LoxPhs3a1,2 or parental clones) were tested for LPS-inducible γ2b expression by 
addition of  LPS to culture medium and measurement of γ2b in cell lysate by ELISA. The 
results for the 14 parental clones tested are shown in Figure 9. At the lowest LPS 
concentration (0.01 µg/mL), 2b expression was unchanged for one clone (pC1) and 
increased between 1.8 and 4 fold over unstimulated levels in the other clones. Expression 
of 2b increased between 2 and 10 fold over unstimulated at an LPS concentration of 0.1 
g/mL. With a LPS concentration of 1.0 g/mL, 2b expression increased between 2 and 
10 fold over unstimulated except for pC4 which showed a 20 fold increase. Clone pC10 
appeared to not express 2b. In three clones, 2b expression appears to decrease at higher 
concentrations of LPS; however, pC5 at 1 g/mL had high variability during total protein 
determination (CV=32%); therefore, the total amount of protein used in the ELISA may 
have been less than 1 g. The decrease in 2b for pC7 and pC16 were unexpected. Given 
the overall low level of 2b expression in pC16 and its lower expression at high 
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concentrations, and its potential to have more than one copy of the 2b transgene, it was 
disqualified from further testing. 
 
Figure 9 LPS-Induced 2b Expression in CH12.LX.2b-LoxPhs3a1,2 Clones:  Clonal isolates 
of cells after introduction of the 2b-LoxPhs3a1,2 and NEO plasmids were screened by ELISA 
for 2b expression after treatment with LPS. Bars are representative of a single treatment with the 
indicated LPS concentration, making statistical comparisons unfeasible. 
Six parental clones (pC2, pC3, pC4, pC5, pC13, and pC17) were screened for the 
effect of TCDD on 2b expression and compared to C3 cells as a positive control. These 
clones were chosen because they displayed a concentration dependent increase in 2b 
expression, appeared to each have a single copy of the transgene, and had no obvious 
reasons to be disqualified. The results are shown in Figure 10. With 95% confidence, each 
LPS+DMSO is significantly greater than its corresponding NA or DMSO, and each 
LPS+TCDD is significantly less than its corresponding LPS+DMSO. 
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Figure 10  Inhibition of LPS-Induced 2b Expression by 10 nM TCDD: Six 2b-LoxPhs3a1,2 
clones were screened for the effect of 10 nM TCDD (in DMSO) on 2b expression. Each clone 
was induced by LPS to express 2b (each LPS+DMSO is significantly greater than its 
corresponding NA or DMSO), and that expression is inhibited by TCDD (each LPS+TCDD is 
significantly less than its corresponding LPS+DMSO) (=0.05) . Each bar represents 4 replicates 
and error bars represent the standard deviation. 
This means that each clone was stimulated by LPS to produce 2b and that stimulation 
was inhibited by TCDD. Only pC17 had a LPS+TCDD significantly different from 
(greater than) its corresponding NA and DMSO, suggesting that in all tested clones 
except pC17, TCDD inhibited 2b expression back to baseline, or pre-stimulation levels. 
pC13 was chosen as parent for the deletion derivatives because it had the least variability 
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in 2b expression and was similar to the C3 positive control in this screen for inhibition 
by TCDD. Cells were not treated with LPS alone for comparison to LPS+DMSO 
treatment in this screening, but previous studies and subsequent studies have shown that 
0.01% DMSO does not significantly alter LPS-mediated activation of CH12.LX cells. 
The hs3a/hs1,2 enhancer pair were removed from the CH12.LX.γ2b-LoxPhs3a1,2 
reporter transgene by transient expression of CRE-recombinase enzyme. The enzyme and 
Green Fluorescent Protein (GFP) reporter were transfected on a pEGFP-CRE plasmid by 
electroporation. The plasmid was linearized by digestion with Hind III (bands expected at 
2.7, 3.0, and 3.4 kilobases). Figure 7 shows the results of a restriction digest conducted 
several months prior to transfection while Figure 11 shows results of a digest just prior to 
transfection. Successfully transfected cells were identified by expression of GFP and 
sorted by FACS. Graphical results of cell sorting are presented in Figure 12. About 
71,000 GFP-expressing cells were recovered. Clonal selection was accomplished by 
limiting dilution in 96-well plates; however, cells that were diluted on the day of sorting 
did not grow. Experience from culturing CH12.LX cells suggests that the cells have 
greater viability when in contact with other cells. I speculate that being electroporated on 
the previous day, sorted through a flow cytometer, and then diluted to isolate single cells 
was too much stress and the cells could not grow. Perhaps mitogenic stimulation would 
have produced clonal isolates from that first batch of cells. Subsequent limiting dilutions 
yielded many colonies, but only 19 were collected with high confidence that they came 
from a single clone instead of a clump of cells. 
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Figure 11 Restriction Enzyme Digestion of the pEGFP-CRE Plasmid: The integrity of the 
pEGFP-CRE plasmid was re-verified just prior to transfection. Column labels show the restriction 
enzyme used and in parenthesis, the expected DNA fragment sizes after digestion with that 
enzyme. 
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Figure 12  FACS of GFP-Expressing Cells: After transfection with the pEGFP-CRE plasmid, 
cells expressing GFP were separated from non-expressors by the Core Flow Cytometry Facility at 
Cincinnati Children’s Hospital (Cincinnati, OH), who provided these graphics. Untransfected 
CH12.LX cells were used as negative control (top 6 panels). Stringent gating to ensure precise 
collection of GFP expressing cells rendered less than 2% of the total cells (lower 6 panels).  
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Deletion of the hs3a/hs1,2 enhancer pair was confirmed by PCR using primers 
that flanked the two LoxP sites (CUT), amplifying a DNA sequence only if the long 
enhancer pair was removed; or primers that amplified part of the sequence inside the 
LoxP-surrounded enhancers (UNCUT), amplifying a sequence only if the enhancer pair 
was not removed. Results of PCR analysis are shown in Figure 13, Figure 14, Figure 15, 
and Figure 16 and summarized in Table 3. The pC13 (parental) negative cut control had a 
product with UNCUT primers and did not have a product with CUT primers. Also in this 
test, the CH12.LX (LX) negative PCR control (which should not have any sequence from 
the transgene present to amplify) had a product with the UNCUT primers (Figure 13). 
This could have been caused by contamination or from spill-over between wells on the 
agarose gel which was noted during gel loading in the initial PCR tests when the entire 
reaction volume was loaded to gels. Only 15 μL was loaded from later tests, no spill-over 
was noted, and the LX did not have a product with the UNCUT primers (Figure 15). In 
addition, the first PCR test used an old stock of Taq DNA polymerase which was at or 
past its expiration date. Only one of the deletion derivative clones isolated from limiting 
dilution (D15) was positive for CUT and negative for UNCUT, indicating the 2b mini-
locus was correctly cut in those cells to remove the hs3a and hs1,2 enhancers. Five of the 
clones (D12, D13, D14, D17 and D18) were positive for UNCUT and negative for CUT, 
indicating that the 2b mini-locus in those cells was not cut. The remaining clones were 
positive for both CUT and UNCUT, indicating either that they had more than one copy of 
the mini-locus, some of which was correctly cut by CRE-recombination and some of 
which was not, or that there was a mixed population of cut and uncut cells. This result 
could not be caused by the deleted segment being reintegrated to the genomic DNA 
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because the forward PCR primer was outside of the deleted segment. Initially, D1 did not 
have a product with UNCUT primers (Figure 14); however, when tested again to confirm 
this finding, it did have a product (Figure 15).   
Seven of the double positive (CUT and UNCUT) clones (D1, D2, D3, D4, D5, 
D16, and D19) underwent the same limiting dilution as the initial proposed deletion 
derivatives and their clonal isolates underwent PCR confirmation. The results are shown 
in Figure 17, Figure 18, Figure 19, and Figure 20, and summarized in Table 4, Table 5, 
Table 6, and Table 7.  The majority of those clonal isolates were either correctly cut or 
uncut, with a few still showing both characteristics. The numbers of isolates correctly cut, 
uncut, and mixed are summarized in Table 8. Since the clones could be separated in to 
populations (cut or uncut), there was likely a mixed population of cut and uncut in the 
original deletion derivative isolates.  
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Table 3 Results of PCR testing of CH12.LX.2b-LoxPhs3a1,2 clones: Clones were tested by 
PCR using primers that surround the LoxP sites of the target deletion to identify correctly cut 
transgenes (CUT) and primers that surround only the 5-prime LoxP site to identify uncut 
transgenes (UNCUT). “+” indicates the presence of a PCR product while “–“ indicates absence of 
PCR product. “+/−” indicates that different results were obtained in replicate tests. “Large” 
indicates the product observed was too large for that primer pair. 
56 
 
 
Figure 13 PCR Test for Deletion of the hs3a and hs1,2 Enhancers from Cell Isolates 
Collected after Limiting Dilution of GFP-Expressing Cells: Isolates were screened by PCR for 
presence of the hs3a and hs1,2 enhancer region which was targeted for deletion by cre-
recombination. The primers CEWS143+144 were found to accurately amplify DNA which had 
been cut while CEWS143+161 accurately amplified DNA which was not cut. In addition, 
CEWS162+163 accurately identified the presence of the hs3b and hs4 enhancer region and 
CEWS157+158 identified a 2b sequence in an hs3b and hs4 deletion derivative (3b4). Many of 
the same clones tested positive for being CUT and UNCUT. 
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Figure 14 PCR Test for the Presence of the hs3a and hs1,2 Enhancers in Cell Isolates 
Collected after Limiting Dilution of GFP-Expressing Cells: Isolates were screened by PCR for 
presence of the hs3a and hs1,2 enhancer region which was targeted for deletion by cre-
recombination. The primers CEWS143+161 were found to accurately amplify DNA which was 
uncut. CEWS159+163 were unable to identify UNCUT clones. 
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Figure 15 PCR Test for the Presence of hs3a and hs1,2 Enhancers in Proposed Deletion 
Derivatives: Cells which were isolated from GFP-expressing cells and were found to have some 
CUT transgenes and some UNCUT transgenes underwent limiting dilution and were 
subsequently screened for the presence of the target hs3a and hs1,2 enhancers. The new isolates 
in this figure originated from the D2, GFP-expressing isolate. Several GFP-expressing isolates 
were also re-screened for the enhancers. In this figure, 11 of the new isolates still have the 
targeted enhancers while 19 do not. CH12.LX cells (LX) acted as negative control.  
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Figure 16 PCR Test for hs3a and hs1,2 Deletion from Proposed Deletion Derivatives: Cells 
which were isolated from GFP-expressing cells and were found to have some CUT transgenes 
and some UNCUT transgenes underwent limiting dilution and were subsequently screened for the 
deletion of the target hs3a and hs1,2 enhancers. Several previously screened GFP-expressing 
isolates and new isolates were also re-screened for the presence or deletion of the targeted 
enhancers. In this figure, 22 of the new isolates tested positive for deletion of the targeted 
enhancers, only 3 of which had also tested positive for presence of the enhancers. 7 did not test 
positive for deletion. CH12.LX cells acted as negative control. 
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Figure 17 PCR Test for hs3a and hs1,2 Deletion from Proposed Deletion Derivatives: Cells 
derived from limiting dilution of GFP-expressing isolates were screened by PCR for deletion of 
the targeted enhancers (CUT). In this figure, the enhancer region was found to be deleted from 28 
of the new clonal isolates. These new isolates came from the GFP-expressing isolates D1, D2, 
D3, D5, D16, and D19. The parental pC13 cells acted as negative control while D2-29 (positive 
in previous tests) acted as positive control. 
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Figure 18 PCR Test for hs3a and hs1,2 Deletion from Proposed Deletion Derivatives: Cells 
derived from limiting dilution of GFP-expressing isolates were screened by PCR for deletion of 
the hs3a and hs1,2 enhancer region (CUT). In this figure, 9 of the new isolates tested positive for 
deletion of the targeted enhancers. These samples were amplified at the same time as the previous 
gels but there was no positive or negative control left to load to this gel. 
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Figure 19 PCR Test for the Presence of the hs3a and hs1,2 enhancers in Proposed Deletion 
Derivatives: Cells derived from limiting dilution of GFP-expressing isolates were screened by 
PCR for presence of the hs3a and hs1,2 enhancer region (UNCUT). In this figure, thirteen of the 
new clonal isolates were found to contain the targeted enhancer region, 9 of which also tested 
positive for deletion. Some of the faint bands were verified by loading a larger volume on another 
gel. D2-29 which tested negative previously served as the negative control and pC13 acted as 
positive control.  
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Figure 20 PCR Test for the Presence of the hs3a and hs1,2 enhancers in Proposed Deletion 
Derivatives: Cells derived from limiting dilution of GFP-expressing isolates were screened by 
PCR for presence of the hs3a and hs1,2 enhancer region (UNCUT). In this figure, 11 of the new 
isolates were found to contain the targeted enhancer region, only 2 of which also tested positive 
for enhancer deletion. Another 11 were verified here after their bands were too light in a previous 
gel. pC13 acted as positive control and the same negative control as the other gels, D2-29, did not 
have enough left to load here. 
64 
 
 
Table 4 Results of PCR testing of the D2 Subclones:  Proposed deletion derivative D2 which 
tested positive for CUT and UNCUT underwent limiting dilution and subclone isolates were 
tested by PCR for modification of the 2b transgene. “+” indicates the presence of a PCR product 
while “–“ indicates absence of PCR product. 
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Table 5 Results of PCR testing of the Various Subclones I:  Proposed deletion derivatives, Dx, 
which tested positive for CUT and UNCUT underwent limiting dilution. Subclone isolates, Dx-y, 
were then tested by PCR for modification of the 2b transgene. “+” indicates the presence of a 
PCR product while “–“ indicates absence of PCR product. 
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Table 6 Results of PCR testing of the Various Subclones II:  Proposed deletion derivatives, 
Dx, which tested positive for CUT and UNCUT underwent limiting dilution. Subclone isolates, 
Dx-y, were then tested by PCR for modification of the 2b transgene. “+” indicates the presence 
of a PCR product while “–“ indicates absence of PCR product. 
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Table 7 Results of PCR testing of the Various Subclones III:  Proposed deletion derivatives, 
Dx, which tested positive for CUT and UNCUT underwent limiting dilution. Subclone isolates, 
Dx-y, were then tested by PCR for modification of the 2b transgene. “+” indicates the presence 
of a PCR product while “–“ indicates absence of PCR product. 
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Table 8 Results of Subclone Testing for 2b Transgene Modification: The table shows the 
number of subclones found to have cut transgenes (+CUT /– UNCUT) or uncut transgenes (– 
CUT/+UNCUT) or mixed cut and uncut (+CUT/+UNCUT) or no transgene (– CUT/– UNCUT).  
Transcriptional induciblility of the 2b transgene was tested by activating cells 
with LPS and measuring 2b protein by ELISA. D15 was the only deletion derivative 
from the initial limiting dilution (isolated after cell sorting and PCR test indicated that the 
LoxP flanked sequence was deleted) did not express 2b after LPS activation. The initial 
ELISA for that deletion derivative was conducted with 1 µg of total protein, so the assay 
was repeated two more times with various amounts of total protein up to 40 µg.  No 2b 
was detected at any amount of total protein. The parent assayed on the same date was 
induced by LPS to express 2b and that expression was inhibited by TCDD (Figure 21), 
so the assay conditions did not prevent 2b expression by D15.  
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Figure 21 LPS-Induced 2b-Expression and Inhibition by TCDD in CH12.LX.2b-
LoxPhs3a1,2-pC13 Cells: The pC13 parental cells were assayed by ELISA for 2b expression 
without treatment (NA) after treatment with LPS or LPS + Vehicle (0.01% DMSO – 0 nM 
TCDD) or LPS + TCDD at different concentrations (0.01, 0.1, 1.0, or 10 nM). LPS induced the 
cells to express 2b (LPS and LPS + 0 nM TCDD were significantly greater than NA). There was 
no vehicle effect (LPS and LPS + 0 nM TCDD treatments were not significantly different from 
each other).  Expression of 2b was inhibited by TCDD at concentrations greater than 0.01 nM 
(LPS + 0.1, 1.0, or 10 nM were significantly less than LPS + 0 nM TCDD). Even at 10 nM 
TCDD, 2b expression was not completely eliminated since it was still significantly greater than 
NA (a=0.05). Error bars represent the standard deviation. 
Since the initial characterization studies were run concurrent with PCR 
confirmation of enhancer deletion, D1 which was initially confirmed as a correctly cut 
clone but later identified as a mixed population of cut and uncut, was tested twice for 
LPS activation. In one test (5/1/09), 2b appeared to be induced at higher LPS 
concentrations, but differences between doses were not statistically significant, and the 
second test showed no increase in 2b at all (Figure 22). In anticipation of transfecting 
additional parental clones for deletion of the hs3a and hs1,2 enhancers, LPS-mediated 
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activation of pC14 and pC15 was confirmed (Figure 23). In addition, CH12.LX cells 
were tested for 2b expression and I found that despite the rtPCR results that show the 
2b gene sequence may be present in CH12.LX cells, they are not induced to produce 2b 
by LPS (data not shown). Even when loading 5 µg of total protein to the ELISA plate, the 
levels of 2b at LPS concentrations up to 10 g/mL were equal to or lower than 
background (negative control). 
 
Figure 22 LPS Does not Induce D1 Deletion Derivative to Express 2b:  D1 cells were a GFP-
expressing isolate which initially appeared in PCR tests to have the hs3a and hs1,2 enhancers 
deleted. They were tested twice for LPS-induced 2b expression by ELISA. The data from 5/1/09 
represents the mean and standard deviation of duplicate samples at each concentration of LPS. 
There is no significant difference between treatments. The data from 5/11/09 represents a single 
sample at each concentration, and there is no increase in 2b expression with increasing 
concentrations of LPS. Subsequent PCR tests proved that D1 was a mixed population of cells: 
some with an uncut 2b transgene and some with the hs3a and hs1,2 enhancers deleted. 
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Figure 23 LPS Induced 2b Expression in CH12.LX.2b-LoxPhs3a1,2-pC14 and –pC15 
Cells: These parental clones, transfected with the 2b transgene, were re-tested for activation by 
LPS in preparation for making additional Cre-recombinate derivatives.  
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Figure 24 First Study of the Effect of LPS and TCDD on Deletion Derivative D2-29 and Its 
Parental pC13: Confirmed deletion derivative D2-29 and its parental pC13 were treated with 
different concentrations of LPS alone or with vehicle (0.01% DMSO) or TCDD (10 nM). 
Expression of 2b was measured by ELISA using 2 g total protein per well. “NO LPS” refers to 
unstimulated cells. “NA” cells were stimulated by the concentration of LPS indicated but not 
treated with vehicle or TCDD. Duplicate treatments are represented here by their mean and 
standard deviation. LPS only induced a significant increase in 2b at 0.1 g/mL LPS in D2-29 
cells, and the apparent decreases in 2b at 0.01 and 0.1 g/mL LPS after TCDD treatment were 
not statistically significant (=0.10). pC13 cells were similar to D2-29 in that LPS induced a 
significant increase in 2b only at 0.1 µg/mL, but in pC13 cells, the decrease in 2b after TCDD 
treatment is significant (=0.05). 
Several deletion derivatives from the second limiting dilution (separating mixed 
populations of cut and uncut derivatives) were found not to express 2b after LPS-
activation: no 2b protein was found even after loading 5 times (5 µg) the total protein 
normally used in the ELISA. (data not shown). The deletion derivative D2-29 was then 
tested for transgene induction at 3 concentrations of LPS and for inhibition by 10 nM 
TCDD, using its parent, pC13, as a control. The results are shown in Figure 24. I 
observed previously that the 2b response reached a plateau in response to LPS at 1 
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µg/mL, so in order to preserve the lot of LPS that I was using, I used the LPS 
concentrations of 0.001, 0.01, and 0.1 µg/mL. Each treatment was done in triplicate, but 
there was high variability in the total protein determination for the first sample in most 
treatments, so any sample greater than 15% CV in total protein determination was 
removed from the final ELISA results. For both pC13 and D2-29, the only significant 
increase in 2b expression was at the highest concentration of LPS (0.1 µg/mL). In 
addition, only at that concentration, TCDD caused a significant decrease in 2b 
expression for both pC13 and D2-29. The LPS concentration response of D2-29 and 
pC13 with 10 nM TCDD was repeated with similar results. Figure 25 shows that 2b 
expression by D2-29 is significantly inhibited by TCDD when activated by 0.01 and 0.1 
g/mL LPS. Even at 0.001 µg/mL LPS, where 2b expression is not significantly greater 
than basal (0.0 µg/mL), it is significantly less in the 10 nM TCDD treatment than its 
vehicle control. The pC13 cells had a lower than usual level of 2b expression after LPS 
treatment, and TCDD only inhibited 2b expression significantly at the highest 
concentration of LPS, which is also the only concentration at which 2b expression was 
significantly greater than basal. There was less variability in the total protein analysis for 
the repeat experiment, and a second protein determination conducted after diluting the 
samples to the concentration used in the ELISA revealed that the D2-29 samples were 
consistently just under the 2 g total-protein target while the pC13 samples were 
consistently just over the 2 g target. 
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Figure 25 Second Study of the Effect of LPS and TCDD on Deletion Derivative D2-29 and 
Its Parental pC13: Confirmed deletion derivative D2-29 and its parental pC13 were treated with 
different concentrations of LPS alone or with vehicle (0.01% DMSO) or TCDD (10 nM). 
Expression of 2b was measured by ELISA using 2 g total protein per well. “NO LPS” refers to 
unstimulated cells. “NA” cells were stimulated by the concentration of LPS indicated but not 
treated with vehicle or TCDD. Duplicate treatments are represented here by their mean and 
standard deviation. With 95% confidence (=0.05), 2b in the pC13 cells only increases 
significantly over basal expression at 0.1 g/mL LPS, while in the D2-29 cells 2b is significantly 
increased at 0.01 and 0.1 g/mL LPS. In this study, TCDD caused a significant decrease in 2b at 
0.1 g/mL LPS in both the pC13 parentals and the D2-29 deletion derivatives. In the D2-29 cells, 
2b is also significantly inhibited by TCDD at 0.01 g/mL TCDD. 
I hoped to see a synergistic increase in 2b expression in the D2-29 clone, similar 
to that which was seen previously in transient transfection studies, but the transgene in 
my first deletion derivative (D2-29) appeared to be inhibited by TCDD, so I conducted a 
screen of all the deletion derivatives in which each was either untreated, treated with 1 
g/mL LPS, or treated with 10 nM TCDD and 1 g/mL LPS. My hope was to identify 
several clones with a cut 2b transgene which was further stimulated by TCDD. Each 
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treatment was conducted in duplicate with plans to further characterize any cells that 
screened positive for activation with TCDD. The 20 isolates of deletion derivatives were 
all treated on the same day and analyzed by ELISA in 4 plates over 2 days. The isolates 
were expected to represent up to 5 different deletion derivative cell lines: D16 was 
represented by 10 isolates; D19 by one isolate; D3 by 4 isolates; D5 by 3 isolates; and D1 
was represented by two isolates. Since each set of isolates had a cut 2b transgene and 
was obtained by limiting dilution of a single mixed population (from mixed populations 
D16, D19, D3, D5, or D1), those derived from the same mixed population but confirmed 
to have a cut transgene were likely to be identical clones, so I expected them to respond 
similarly (each identical clone being affected similarly). That proved true for 3 of the 5 
deletion derivative clones. None of the isolates from D16 expressed 2b. Deletion of the 
hs3b and hs4 enhancers from the 2b-LoxPhs3b4 transgene also produced many clonal 
isolates that no longer expressed 2b (Fernando, personal communication), so it was no 
surprise to find a deletion derivative that did not express 2b. The single isolate from D19 
and the 3 isolates from D5 also did not express 2b. Surprisingly, one of the two isolates 
from D1 did not express 2b, nor did one out of the 4 isolates from D3. D1-11 which 
expressed 2b increased expression by 4 fold when treated with LPS, and was 
significantly inhibited by TCDD (Figure 26). Of the 3 isolates from D3 which expressed 
2b, D3-4 and D3-9 responded similarly with about a 2 fold increase in expression after 
LPS treatment and not a significant change when TCDD was added (Figure 26). D3-16 
had a 4 fold increase in expression with LPS and not a significant change when TCDD 
was added. Expression of 2b in pC13, the parental cells tested on the same day, was 
significantly inhibited by TCDD (Figure 26). 
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No deletion derivative was found to have a synergistic increase in 2b expression 
with LPS and TCDD, but one deletion derivative, with at least 2 differently responding 
subtypes, does not appear to be significantly inhibited by TCDD under these treatment 
conditions.  
 
Figure 26 The Effect of LPS and TCDD on Various Deletion Derivatives and Their Parental 
pC13: 20 isolates of confirmed deletion derivatives and their parental pC13 were either untreated, 
treated with LPS alone or with 10 nM TCDD. Expression of 2b was measured by ELISA using 2 
g total protein per well.  Only 4 of the 20 isolates tested expressed 2b: 3 came from the same 
proposed deletion derivative (D3) and one came from another (D1). There was also one isolate 
from D3 and one from D1 which did not express 2b. In this figure duplicate measurements are 
presented side by side instead of presenting them as a mean and standard deviation. Expression of 
2b in all of the deletion derivative isolates and pC13 increased significantly after LPS treatment 
but only pC13 and D1-11 were significntly inhibited by TCDD (=0.05). 
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The second specific aim proposing a qualitative shift in the binding of NFB/Rel 
proteins to the hs4 and hs1,2 enhancers after TCDD exposure was addressed using the 
Electrophoretic Mobility Shift Assay (EMSA). This study began with optimization of 
binding conditions for the hs4 probe in an attempt to replicate published results(Sulentic, 
et al., 2000) with the addition of stimulation by LPS, which was not tested previously. 
My first EMSA (Figure 27) used nuclear protein from CH12.LX cells treated with 10 nM 
TCDD. Poly[d(I-C)] concentrations were 0.5, 1, and 2 g and the KCl was meant to vary 
between 90 and 110 mM, but a miscalculation resulted in concentrations ranging from 
129 to 165 mM. In addition, because of the method used to put together the binding 
reaction and dilute the proteins, the HEPES and EDTA concentrations varied between 
groups of samples from 15 to 20 mM HEPES and 0.6 to 0.8 mM EDTA. The glycerol 
percentage also varied between samples. This experiment did show that proteins will bind 
the hs4 probe under diverse and less than optimal conditions. 
The mistakes were not realized until later, so my next two experiments also had 
incorrect salt, HEPES, EDTA, and glycerol concentrations (Figure 28). In addition, the 
phosphoimager plates were causing lines and varying densities of response within the 
gels which eventually caused me to change to autoradiography film. Although a light spot 
on the imaging plate interfered with the results, a time course for the binding reaction 
suggested that there was not much difference in binding between 15, 30, 45 and 60 
minute incubation times (Figure 28, right gel, right end of gel), so subsequent binding 
reactions were incubated between 30 and 45 minutes.  
The calculation mistakes were corrected and the method for making the binding 
reaction improved by making a reaction mix with the HED, glycerol, DTT, poly[d(I-C)], 
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and HEDK, so that each diluted protein got the intended reagent concentrations (10 mM 
HEPES, 1 mM EDTA, variable KCl). Figure 29 shows the first optimization-EMSA with 
correct reagent concentrations. It also shows that binding appeared to increase when cells 
were treated with TCDD or LPS and decrease approximately back to baseline (NA) when 
cells were treated with both TCDD and LPS. Those differences between treatments are 
most apparent at 90 mM KCl.  
Published work with the hs4 enhancer (Sulentic, et al., 2000) suggested that the 
band caused by AhR binding and the band caused by NFB/Rel binding should be 
somewhat distinguishable from each other. Since two bands were not distinguishable in 
my results, I added conditions to try and tease apart those bands while continuing to 
optimize binding conditions. Figure 30, left gel, shows a study optimizing poly[d(I-C)] 
concentration while also adding excess unlabeled DRE3 probe to bind up AhR and see if 
the binding pattern changed. Antibodies to AhR or p65 or p50 were also added to some 
reactions to try and change the migration of bands (supershift) corresponding to those 
proteins. I chose 90 mM KCl for this experiment because of a clear difference in binding 
between treatments in the previous experiment at 90 mM KCl (Figure 29) and the lack of 
a vehicle effect at 90 mM that is apparent at 100 and 110 mM KCl. In this experiment, 
the proteins from vehicle treated cells have a more intense band than NA cells (Figure 30, 
left gel), suggesting a vehicle effect at 90 mM KCl that was not apparent in the previous 
experiment. DRE3 unlabeled competitor seemed to affect band intensity only slightly, 
suggesting that there may be some DRE binding, but its band was not discernable from 
overlapping bands. The antibodies did not appear to supershift any bands, suggesting that 
either those proteins were not binding, or that conditions needed to be optimized to see a 
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supershift. There was also no apparent difference between poly[d(I-C)] concentrations, so 
I chose 1 µg/mL for most subsequent studies to replicate the published data. Interestingly, 
the gel on the right in Figure 30 which did not have unlabeled competitors or antibodies 
to differentiate the binding of multiple proteins, appears to have two distinguishable 
bands.  Also note that this experiment involved an altered hs4 probe: the top strand had 
additional nucleotides (GAT) on its 5-prime end to create an overhang of unmatched 
nucleotides. Use of overhangs had been recommended to the lab for improved labeling 
efficiency. Two a dditional experiments were conducted with this “overhang” probe in 
which electrophoresis ran longer and the gels were unreadable (not shown), likely due to 
increased resistance in the ion-depleted buffer which generated heat in the gel. 
Thereafter, the buffer in the upper reservoir was periodically replaced with fresh buffer. 
In published literature, overhangs are used to label probes by filling them with radio-
labeled dNTP using Klenow enzyme (Liao, et al., 1992; Singh, et al., 1993; Sovak, et al., 
1997; Tian, et al., 1999; Urban, et al., 1990; Grant, et al., 1992; Kretzschmar, et al., 1992; 
Davarinos, et al., 1999; Ruby, et al., 2002; Lin, et al., 1992; Woo, et al., 2002) and I was 
concerned about proteins sticking non-specifically to the unfilled overhangs on our probe, 
so I discontinued use of the hs4 overhang probe. One additional change was that glycerol 
was removed from the binding reaction. Since I had been using a loading dye to transfer 
samples from the reaction tubes to the gel, I did not need glycerol in the reaction itself. 
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Figure 27 Initial EMSA Optimization with Variable Reagent Concentrations: Due to 
miscalculation and the method by which the binding reaction was put together, this initial EMSA 
had too much reagent variability; however, this shows that under diverse conditions, proteins will 
still bind the probe. Nuclear proteins from TCDD treated CH12.LX cells were collected by the 
homogenizer method. Reaction products were separated on a 4% polyacrylamide gel and 
documented on a FujiFilm FLA5100. 
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Figure 28 Initial EMSA Optimization Showing Variable Reagent Concentrations and 
Imager Anomalies: Miscalculation and method development issues caused reagent variability in 
these EMSA results. Nuclear proteins were collected from CH12.LX cells by the homogenizer 
method after no  treatment (NA), treatment with  vehicle (Vh), 1 µg/mL LPS (L), 10 nM TCDD 
(T), or with both LPS and TCDD (LT). “No” indicates there was no protein added to that binding 
reaction. Reaction products were separated on 4% polyacrylamide gels and documented on a 
FujiFilm FLA5100.  Note the lines and variable image density which continued to be a problem 
with the phosphoimaging plates, leading to an eventual change to autoradiography film. 
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Figure 29 Optimization of the EMSA for the hs4 probe: Nuclear proteins from CH12.LX cells 
were collected by the homogenizer method after no treatment (NA) or treatment with vehicle 
(Vh), 10 nM TCDD, 1 µg/mL TCDD, or LPS and TCDD (LT). There were incubated with the 
hs4 probe in 25mM HEPES, 1 mM EDTA, 1 mM DTT, 10% glycerol,  and either 90, 100, or 110 
mM KCl. “No” indicates no protein was added to the binding reaction. Reaction products were 
separated on a 4% polyacrylamide gel and documented on a FujiFilm FLA5100. 
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Figure 30 Optimization  and Characterization of the hs4 Probe with an Overhang: The 
probe use in these experiments had an “overhang” of unpaired nucleotides. Nuclear protein was 
isolated from CH12.LX cells by the homogenizer method after no treatment (NA) or treatment 
with vehicle (Vh), 10 nM TCDD, 1 µg/mL LPS and vehicle, or 1 µg/mL LPS and 10 nM TCDD. 
“No” indicates that no protein was added to the binding reaction. The proteins were incubated 
with the overhung hs4 probe in 10 mM HEPES, 1 mM EDTA, 1 mM DTT, variable amounts of 
poly[d(I-C)], and variable concentrations of KCl. Where indicated, unlabeled probes were added 
as binding competitors or antibodies were added for a supershift. Reaction products were 
separated on a 4% polyacrylamide gel and documented on a FujiFilm FLA5100. 
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Figure 31 EMSA with hs4 and DRE3 probes: Nuclear proteins from CH12.LX were collected 
by the homogenizer method after no treatment (NA) or treatment with vehicle (Vh), 10 nM 
TCDD (T), 1 µg/mL LPS (L), or LPS and TCDD (LT). “No” indicates that no protein was added 
to the binding reaction. Proteins were incubated with the hs4 probe or DRE3 probe in 10 mM 
HEPES, 1 mM EDTA, 1 mM DTT, 1 µg/mL poly[d(I-C)], and 90 mM KCl. Where indicated, 
unlabeled probe was added as a binding competitor. Reaction products were separated on a 4% 
polyacrylamide gel and documented on a FujiFilm FLA5100. 
I next labeled the DRE3 probe, hoping to confirm that the protein samples did 
have AhR, since only the AhR protein (and binding partner) should bind to the DRE3 
probe. Figure 31 shows that nuclear proteins bound the DRE3 probe form two differently 
migrating bands. The upper band was missing for the untreated cells but present for cells 
treated with vehicle, TCDD, LPS, or LPS and TCDD.  TCDD and LPS are both known to 
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stimulate AhR expression(Sulentic, et al., 1998; Marcus, et al., 1998; Sulentic, et al., 
2000), so the upper band appeared to correspond to AhR binding; however, that same 
band appears in most of the samples across the gel including the proteins from untreated 
(NA) cells bound to the hs4 probe. The band’s intensity does seem reduced when 
unlabeled DRE3 is present with the hs4 probe, but not when the unlabeled hs4 probe is 
the competitor, which is suggestive of non-specific binding or differing affinity of the 
binding complex for DRE sites. The faster migrating band in this gel acts similar to 
previous experiments with the hs4 probe, but its appearance with the DRE3 probe is 
different: not as wide, nor as dense, nor as predictable of a pattern. 
I decided to change to autoradiography film and use a higher concentration of 
KCl (130 mM) hoping that more total binding at the higher KCl concentrations would 
allow easier teasing out of AhR binding. In Figure 32, I used the hs4 and DRE3 labeled 
probes in combination with unlabeled hs4, DRE3, DRE4, or B (huhs1,2kb – see Table 
1- was used because I did not have the consensus B probe yet) to discern which proteins 
correspond to different bands or areas within a band. I used proteins from cells exposed 
to 1 g/mL LPS and 10 nM TCDD (LT), in which I expected to have both NFB/Rel and 
AhR proteins in high concentration, and cells exposed to 1 g/mL LPS and vehicle (LV) 
because I wanted to see what proteins were binding in the apparent vehicle effect.  
I included the hs4s probe as an unlabeled competitor because its 5-prime end starts at the 
B site and I wondered if that might alter the B binding of that probe. There was no 
difference in results between the LT and LV samples for the hs4 probe. When unlabeled 
hs4 or hs4s probe was included, proteins did not bind the labeled probe, so the bands 
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were likely caused by specific binding. When the DRE3 or DRE4 unlabeled probes were 
used as competitors, there was no change in the bands from hs4 probe without unlabeled 
competitor. When the B unlabeled probe was used, the bands were eliminated, which 
indicated that the bands were likely caused by NFB/Rel proteins. Interestingly, when a 
LV sample was incubated with DRE3 probe, no binding occurred, suggesting that the 
vehicle effect does not involve AhR protein; however, there is a bright residual band at 
the loading well for that lane which I am unable to explain. In summary, only probes with 
B binding sites appear to compete for binding of proteins with the hs4 probe, in these 
samples. 
The published study which I was trying to reproduce and develop further, treated 
cells with 30 mM TCDD, so I increased my treatment concentration. I also tested 1 hour 
treatment versus 2 hour treatment. The results are shown in Figure 33. The hs4s probe 
had less binding than the hs4 and was not utilized after this study. While there was no 
clear difference for any sample between its binding of labeled probe and binding in the 
presence of unlabeled competitor with a DRE binding site, the binding was reduced for 
each sample when the unlabeled competitor had a B binding site. The labeled DRE3 
probe was clearly bound by proteins from TCDD treated cells, indicating there is AhR in 
the sample which is available to bind a DRE site. Perhaps the NFB/Rel binding was so 
great for these samples that the DRE binding was overwhelmed so that eliminating DRE 
binding through unlabeled competition did not impact band intensity. Furthermore, the 
hs4 probe has overlapping DRE and B binding sites. Competing out the DRE binding 
does not necessarily mean that less total probe is bound: it means that less probe is bound 
by AhR, which could leave room for more B binding. 
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I conducted an EMSA/Western to better identify the proteins and where their 
bands were migrating in the gel. In the published study(Sulentic, et al., 2000), the 
EMSA/Western showed that the AhR band migrated slightly slower than the NFB band. 
In my first EMSA/Western (Figure 34) the EMSA gel was documented on 
autoradiography film but the Western blot was digitally documented on the FujiFilm LAS 
3000 Image Reader, and that caused great problems in trying to match the image sizes 
and line up the loading wells. Assuming the line-up was correct, AhR appears to migrate 
close but slightly slower than RelA. AhR appears to increase binding with TCDD or LPS 
treatment more than with the combined treatment. RelA appears to only increase binding 
with TCDD treatment.  
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Figure 32 EMSA with the hs4 and DRE3 Probes and Various Unlabeled Competitors: 
Nuclear proteins from CH12.LX cells were collected by the homogenizer method after treatment 
with 1 g/mL LPS and 10 nM TCDD (LT) or 1 g/mL LPS and vehicle (LV). “No” indicates no 
protein was added to the binding reaction. Proteins were  incubated with the hs4 probe or DRE3 
probe in 10 mM HEPES, 1 mM EDTA, 1 mM DTT, 1 g/mL poly[d(I-C)], and  130 mM KCl. 
Where indicated unlabeled competitor probes were added. The unlabeled B probe was 
CEWS80+81, huhs1,2B. Reaction products were separated on a 4% polyacrylamide gel and 
documented on autoradiography film. 
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Figure 33 EMSA with the hs4 and DRE3 Probes and Unlabeled Competitors at a 30 nM 
TCDD Treatment: Nuclear proteins were collected from CH12.LX cells by the homogenizer 
method after no treatment (NA) or treatment with 30 nM TCDD for 1 hour (T1) or for 2 hours 
(T2). Proteins were incubated with the hs4, hs4s, or DRE3 probe in 10 mM HEPES, 1 mM 
EDTA, 1 mM DTT, 1 µg poly[d(I-C)], and 130 mM KCl. Where indicated, unlabeled DRE3 or 
B (huhs1,2B ) probe was added. Reaction products were separated on a 4% polyacrylamide gel 
and documented on autoradiography film. 
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Figure 34 EMSA/Western to Study the Binding of AhR and RelA: Nuclear proteins from 
CH12.LX cells were collected by the homogenizer method after no treatment or treatment with 
30 nM TCDD or 1 µg/mL LPS  or both LPS and  TCDD. Proteins were incubated with the hs4 
probe with or without radio-label, in 10 mM HEPES, 1mM EDTA, 1 mM DTT, 1 µg poly[d(I-
C)], and 130 mM KCl. Unlabeled competitors were used in the EMSA portion of this experiment 
but here the lanes were removed from the gel image (scanned autoradiography film) to simplify 
the picture. Reaction products were separated on a 4% polyacrylamide gel and documented on 
autoradiography film. The Western blot was accomplished with antibody to AhR or RelA (p65) 
after transfer of unlabled, bound probe from the polyacrylamide gel to a PVDF membrane.  The 
Western blots were documented on a FujiFilm LAS 3000 Image Reader . 
I decided to increase the amount of polyacrylamide in my EMSA gels because 
molecules that are close in size are better separated in gels with smaller pore sizes. In 
addition, I started testing the hs1,2 probe to see if the same binding patterns would be 
found with that probe, whose B and DRE binding sites are further apart than the hs4. I 
thought that perhaps the NFB/Rel proteins were out-competing AhR for binding to the 
overlapping sites on the hs4 probe, so that in the presence of a B unlabeled competitor, 
more AhR could bind but in the presence of a DRE unlabeled competitor, no change in 
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binding could be detected. Figure 35 shows two EMSA/Western experiments with 
duplicate reaction conditions whose products are separated on a 4% or 6% 
polyacrylamide gel. Although the autoradiography film may have been overexposed, it is 
still apparent that the bands were better defined on the 6% gel; however, only one band 
could be distinguished for the hs1,2 probe and one large banding area for the hs4. The gel 
to the right shows the Western blot results of this study which was documented on 
autoradiography film. There are spots that seem to correspond to AhR and to RelA at the 
same migration as the EMSA bands for 6% polyacrylamide and the hs4 probe, and 
possibly for the 4% gel with hs1,2 probe, but other spots do not match the migration of 
their EMSA counterpart, which causes doubt as to the identity of all the spots. Markings 
for the loading wells poorly transferred to the film, so lining up the Western gel image 
with the EMSA gel image was difficult. It was also difficult to label the Western gel 
during transfer to the membrane so that the order of wells was not inverted. In addition, 
because the sample volume was limited for this experiment, I had to use protein from 
LPS treated cells in the EMSA but from LPS and TCDD treated cells in the Western. 
Since my main purpose was to see the assay work and identify different migrations for 
the NFB/Rel and AhR proteins, the differing samples were not a concern, but with 
limited success in the assay, interpretation became even more difficult with unmatched 
samples. 
92 
 
 
Figure 35 EMSA/Western with 4% or 6% Polyacrylamide Gels: Nuclear proteins from 
CH12.LX cells were collected by the homogenizer method after no treatment (NA) or treatment 
with 1 µg/mL LPS (L) or with 1 µg/mL LPS and 30nM TCDD. “No” indicates no protein was 
added to the binding reaction. Proteins were incubated with the hs4 probe or hs1,2 probe in 10 
mM HEPES, 1 mM EDTA, 1 mM DTT, 1 µg poly[d(I-C)], and  130 mM KCl (hs4 probe) or 106 
mM KCl (hs1,2 probe). Reaction products were separated on either a 4% or 6% polyacrylamide 
gel and documented on autoradiography film. The Western blot was accomplished with antibody 
to AhR or RelA (p65) after transfer of unlabeled, bound probe from the polyacrylamide gel to a 
PVDF membrane.  The Western blots were documented on autoradiography film. 
Having somewhat mixed results, I wanted to increase my protein yield from each 
treatment so that multiple EMSA experiments could be run using the same protein batch, 
thus eliminating one possible source of variation. In the literature, some conduct nuclear 
protein extraction for EMSA using non-ionic detergent to lyse the cell membrane (Ruby, 
et al., 2002; Feng, et al., 2004; DiDonato, et al., 1995; Kistler, et al., 1998; Ruby, et al., 
2002) and some use a homogenizer (Ashida, et al., 1998; Sulentic, et al., 2000)  and some 
use both (Grumont, et al., 1999). Other graduate students in this laboratory indicated that 
their protein yield was much greater using a non-ionic detergent, so I developed a method 
similar to the homogenizer method I was using, but using the non-ionic detergent 
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IGEPAL CA630 to lyse cell membranes. In addition, some EMSA binding reactions in 
the literature contain non-ionic detergents (Fujita, et al., 1992; Grigoriadis, et al., 1996), 
so I was not concerned about carryover from the protein extraction affecting my EMSA 
results. 
I also questioned my choice of 130 mM KCl, and conducted a study with the new 
protein extraction method comparing 100 and 130 mM KCl with the hs4 and DRE3 
probes, adding DRE3 unlabeled competitor, and including the protein from treated 
primary splenocytes to see if there was any binding from those samples. I also wanted to 
check the difference between 10 and 30 nM TCDD treatments.  Figure 36 shows the two 
gels from that experiment. In the 10 nM TCDD gel, the band representing bound probe is 
generally denser at 100 mM KCl than at 130 mM KCl; however, there is no difference 
between protein from cell treated with vehicle, TCDD, or LPS and TCDD. In the 30 nM 
TCDD gel, there is no obvious difference between 100 mM or 130 mM KCl. There is 
also no discernible difference between treatments. While it appears that at 100 mM, 
unlabeled DRE3 probe competed for binding of the hs4 probe, the wells of that gel were 
poorly formed and that sample may have combined with the splenocyte sample next to it. 
Likewise for well 12 of the 30 nM TCDD gel (130 mM KCl, DRE3 probe): it may have 
combined with some of the LT sample with hs4 probe next to it. The altered migration in 
that lane may be a reaction between the two different probes and protein samples. 
Consistent with previous studies, the DRE3 probe was bound in samples from cells 
treated with 30 nM TCDD but not with 10 nM TCDD. The only well in the 10 nM TCDD 
gel with DRE3 probe and no unlabeled competitor is at 130 mM KCl, because there was 
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not enough probe for the 100 mM KCl sample, but no proteins appear to bind the probe 
from cells treated with 10 nM TCDD under those conditions. 
 
Figure 36 EMSA Comparing 100 and 130 mM KCl and 10 and 30 nM TCDD with the hs4 
and DRE3 Probes: Nuclear proteins collected by the nonionic detergent method, from CH12.LX  
cells treated with vehicle (Vh) or TCDD (T) or 1 µg/mL LPS and TCDD (LT) or from mouse 
splenocytes treated with 30 nM TCDD (Sp) were incubated with hs4 or DRE3 probe in 10 mM 
HEPES, 1 mM EDTA, 1 mM DTT, 1 g poly[d(I-C)], and 100 or 130 mM KCl. Reaction 
products were separated on a 4% polyacrylamide gel and documented on autoradiography film. 
“No” indicates no protein was added to the binding reaction. 
I was still getting variability with the hs4 probe and still not able to replicate what 
had been published for that probe, so I chose to optimize conditions for the hs1,2 probe 
while deliberating options for the hs4. Discussions with other researchers helped me 
realize that I did not need to reduce the HEPES concentration in my samples from the 
protein extraction to the binding reaction, so I used 25 mM HEPES for subsequent 
reactions. I was also advised that DNA loading dyes might interfere with migration of my 
EMSA products, so I stopped using loading dye and starting adding 10% glycerol to the 
binding reaction.  Figure 37 shows the optimization of KCl concentration for the hs1,2 
probe along with the other new conditions just mentioned. At 175 mM, the bands and the 
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entire lane are darker than all the other samples. That sample may have received too 
much probe since the unbound probe appears more abundant at the bottom of the gel as 
well. Looking at the lower bands, I might have chosen 200 mM KCl as optimal because 
the bands are darkest and there is a clear difference between treatments. The upper band, 
though, is more likely the relevant band here because in the 30 nM TCDD lane, only the 
upper band remains visible. I did not employ an unlabeled-probe competitor lane to help 
distinguish between specific and non-specific bands this time because there was not room 
on the gel. I chose 100 mM KCl as optimal because the upper bands are darkest and 
lower bands are still visible. Protein from cells treated with 10 nM TCDD was used 
because there was more available, but the single lane with protein from 30 nM TCDD 
treated cells demonstrates that binding is clearly increased at that concentration.  
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Figure 37 Optimization of the KCl Concentration for EMSA of the hs1,2 Probe: Nuclear 
protein was isolated from CH12.LX cells by the non-ionic detergent method after treatment with 
10 nM (T) or 30 nM (30T) TCDD or 10 nM TCDD and 1 µg/mL LPS. Proteins were incubated 
with the hs1,2 probe in 25 mM HEPES, 1 mM EDTA, 1 mM DTT, 1 µg poly[d(I-C)], 10%  
glycerol and variable concentrations of KCl. Reaction products were separated on a 4% 
polyacrylamide gel and documented on autoradiography film. 
Turning back to the hs4 probe, I studied the binding of proteins from cells 
exposed to other AhR ligands. Indolo(3,2,b)carbazole, Primaquine, Carbaryl, and  
Omeprazole are known to alter expression of a transient reporter regulated by the 3-prime 
enhancers (Henseler, et al., 2009), so I tested them in the EMSA to see if they affected 
binding of the hs4 probe in a different way than TCDD which would help me understand 
the EMSA binding profiles. The initial EMSA with these compounds showed the same 
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effect as TCDD: binding of the hs4 probe which was not reduced by a unlabeled 
competitor with a DRE site (data not shown). Figure 38 shows quite variable results, but 
in general, even when an unlabeled B competitor is present to inhibit binding of rel 
proteins to the probe, there is binding to the hs4 probe which is not eliminated by 
addition of unlabeled DRE competitor. Antibody for AhR seemed to cause a large 
increase in binding.  
 
Figure 38  EMSA with the hs4 Probe and Cells Treated with AhR Ligands: Nuclear proteins 
were isolated by the non-ionic detergent technique from CH12.LX cells after treatment with 
DMSO vehicle (D), or Omeprazole (O), or Carbaryl (C), or Primaquine (P) or 
Indolo(3,2,b)carbazole (I) or TCDD (T). “No” indicates no protein was added to the binding 
reaction. “T+” indicates that the protein came from TCDD treated cells and unlabeled hs4 probe 
was added to the binding reaction. The proteins were incubated with the hs4 probe in 25 mM 
HEPES, 1 mM EDTA, 1 mM DTT, 1 µg poly[d(I-C)], 10% glycerol, and 100 mM KCl. 
Unlabeled competitor probe or anti-AhR antibody was added where indicated. The unlabeled B 
competitor was the consensus B probe. Product was separated on a 4% polyacrylamide gel and 
documented on autoradiography film. 
Hoping that reducing the total amount of binding would help me see the 
differences in binding between treatment groups, I conducted a study to see if increasing 
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the amount of poly[d(I-C)] would help reduce the total binding. Figure 39 shows the 
results of this experiment. For both the hs4 and hs1,2 probes, increasing the amount of  
poly[d(I-C)] caused a decrease in total binding and an apparent shift in band migration, 
although the bands may not actually shift, but simply become more visible as the large 
non-specific band close to it disappears. Moreover, at the highest amount of poly[d(I-C)], 
two bands were distinguishable for each probe, and the hs4 band looked more like the 
“shouldered” bands I was trying to reproduce from the publication. Clearly, using a 
greater amount of non-specific competitor would clarify my EMSA results.   
In collaboration with another graduate student, and confident that I knew the 
optimal binding conditions for the hs1,2 probe, I turned my EMSA efforts toward the 
human hs1,2 probe sequences. Figure 40 shows an EMSA comparing the binding of 
proteins from untreated (NA) cells or cells treated with vehicle (Vh) or 30 nM TCDD (T) 
to the human and mouse hs1,2 probes. In this experiment, it appears that the mouse hs1,2 
sequence was greatly bound in each treatment. The human hs1,2 sequence containing 
both a B and DRE site was bound greater with NA samples than with Vh or T samples, 
but less than when the probe only contained one or the other binding site. In fact, the 
greatest binding occurs when only the B site was present on the probe. Note that the 
“DRE only” and “B only” probes used in this experiment were half the length of the 
“DRE & B” probe. This is because the binding sites are sufficiently distant that simply 
cutting the “DRE & B” probe in half provided the single site probes. That difference in 
size may have contributed to the difference in binding between the double and single site 
probes. The figure also shows with the single-site probes that less AhR is bound than the 
NFB/Rel proteins. 
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Figure 39 Re-optimization of the hs4 and hs1,2 Probes: Nuclear proteins were isolated by the 
non-ionic detergent technique from CH12.LX cells after treatment with 1 µg/mL LPS (for the 
hs1,2 probe) or 30 nM TCDD (for the hs4 probe) and incubated with either the hs4 or hs1,2 
probe. The  binding reaction was 25 mM HEPES, 1 mM EDTA, 1 mM DTT, 10% glycerol, and 
the poly[d(I+C)] and KCl concentrations varied as indicated. Reaction products were separated 
on a 6% polyacrylamide gel and documented on autoradiography film. 
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Figure 40  EMSA with Mouse and Human hs1,2 Probes: Nuclear proteins were isolated by the 
non-ionic detergent technique from CH12.LX cells after no treatment (NA) or after treatment 
with vehicle (Vh) or 30 nM TCDD (T) and incubated with one of the hs1,2 probes: the mouse 
hs1,2 has both a DRE and B binding site; the human hs1,2 probes either have one or both 
binding sites. The  binding reaction was 25 mM HEPES, 1 mM EDTA, 1 mM DTT, 10% 
glycerol, 2 µg poly[d(I+C)], 80 mM KCl. Reaction products were separated on a 5% 
polyacrylamide gel and documented on autoradiography film. 
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Figure 41 EMSA Comparing the Binding of Altered hs4 Sequences: Nuclear proteins were 
isolated from CH12.LX cells by the non-ionic detergent method after no  treatment (NA) or 
treatment with vehicle (Vh) or 30 nM TCDD (T), or 1 µg/mL LPS, or LPS and vehicle (LV) or 
LPS and TCDD (LT). “No” indicates no protein was added to the binding reaction. Proteins were 
incubated with probes for the mouse hs4 enhancer with altered binding sites in 25 mM HEPES, 1 
mM EDTA, 1 mMDTT, 1 µg poly[d(I-C)], 10% glycerol, and 100 mM KCl. Antibody to AhR or 
RelA (p65) was added where indicated for supershift. Reaction products were separated on a 5% 
polyacrylamide gel and documented on autoradiography film. 
Concurrent with the human sequence and poly[d(I-C)] optimization studies I 
decided to see if altering the binding sites on the hs4 probe would help me understand 
what changes might be occurring in binding patterns between treatments. Figure 41 
shows the result of that experiment. Although it is still difficult to make comparisons 
between treatments for the wild type hs4 probe, the probe with a mutated B site clearly 
has an altered binding pattern: with TCDD treatment, there appears to be more binding 
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with the missing B site while with LPS and TCDD treatment there appears to be less 
binding with the missing B site. In both treatment groups, there was a great increase in 
binding when the DRE site was mutated. This supports the theory I explained earlier in 
which NFB proteins and AhR compete for binding of the overlapping sites of the hs4 
enhancer. When one is not able to bind, binding of the other increases, so long as 
sufficient protein is present.  The addition of antibody to AhR did not change binding in 
the T or LT treatment groups, but antibody for RelA (p65) caused a supershift such that 
much of the labeled probe was still near the loading well in those lanes. I know from 
previous studies that AhR is in the nucleus and will bind a DRE site (DRE3 probe), and 
from published studies that AhR will bind the hs4 probe, but with experiments like that in 
Figure 41, it seems that the amount of AhR binding the hs4 probe is very small when 
NFB/Rel proteins are also bound. Furthermore, binding to the hs4 probe which has a 
mutated B site is reduced to a greater extent when cells are co-treated with LPS and 
TCDD than with TCDD alone. Since LPS treatment should cause an increase in 
NFB/Rel proteins in the nucleus, perhaps an interaction between AhR proteins and the 
abundant unbound NFB/Rel proteins (because their binding site has been mutated) 
causes less AhR to bind the probe, and thus the enhancer. If that is true, and AhR inhibits 
the hs4 enhancer, such an interaction (which reduces the AhR binding to hs4) might 
explain the synergistic increase in reporter expression associated with published transient 
expression studies(Sulentic, et al., 2004). 
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Conclusions 
I was able to successfully produce deletion derivative clones which stably 
expressed hs3b/hs4-regulated 2b when activated by LPS. Unlike transient transfection 
studies, the cells stably expressing γ2b under hs3a/hs4 regulation were either inhibited or 
not affected by TCDD. In this stable expression system, the hs3b enhancer is paired with 
the hs4 enhancer, but in the transient expression studies which showed synergistic 
activation, the hs4 enhancer were isolated on a luciferase reporter plasmid. The presence 
of hs3b may have altered the response of hs4 to TCDD treatment. In addition, the 
transgene may have responded differently because of its presence in the context of 
chromatin in this study or by the use of a full-length hs4 sequence while a truncated hs4 
was used in the transient experiments. There may also have been unpredicted 
modifications caused by CRE-recombination that altered the response to TCDD. 
I was unable to show a difference in NFB/Rel subunits that bind to enhancer 
sequences after TCDD treatment. My results were highly variable; however, some of the 
experiments were conducted for optimization of assay conditions, and many were 
conducted to troubleshoot or clarify the binding that occurred, so every treatment 
condition was not included in each experiment, and controls such as probe alone or 
unlabeled competitor were sometimes left out to make room for more samples. 
One possible reason for not seeing clear differences in binding is that in the 
EMSA, proteins have an abundance of binding sites in conditions that favor binding, so 
subtle differences in protein concentrations are masked. Moreover, if the difference in 
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binding is related to the different affinities of AhR and NFB/Rel proteins for their 
binding sites, then competition for the overlapping binding sites in the hs4 enhancer may 
be masked by the excess of sites. One additional step I would like to try is altering the 
total amount of protein and the amount of labeled probe in the reaction. Perhaps if the 
ratio of protein to probe is properly balanced, the proteins will truly have to compete for 
binding sites. 
Another possible explanation was pointed out by Tian in a recent review(Tian, 
2009): interaction between NFB/Rel and AhR does not necessarily inhibit binding of 
either protein to its DNA recognition site. The protein might bind, but because of an 
association with the other protein, another signal that is necessary to initiate transcription 
is blocked. If the dichotomy in effects of TCDD on individual enhancers is related to 
accessibility of binding sites for additional transcription factors, the EMSA would not 
reveal that difference.  
The EMSA/Western was a difficult assay to master. Improvements to this 
technique might include using a larger membrane transfer rig to avoid cutting and 
handling the somewhat fragile EMSA gel or to use antibodies that have been validated to 
bind the target proteins while they are bound to DNA. I would much prefer to use 
supershifts, unlabeled probes, and the mutation of binding sites to identify bound proteins 
given the difficulties I experienced conducting the Western.  
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